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Abstract
The aim of this thesis has been to characterise nanoparticles (NPs) to which tyrosine
hydroxylase (TH) was attached, as a preliminary step in their evaluation to be used for
an enzyme replacement therapy (ERT) for Parkinson’s disease (PD). TH is the enzyme
catalysing the rate-limiting step in the synthesis of catecholamines, an important group
of neurotransmitters. It converts dietary L-tyrosine to L-3,4-dihydroxyphenylalanine (L-
DOPA). Levels of dopamine, one of the catecholamines, are low in the brain of patients
with PD. Typical treatment is the supply of L-DOPA, at least short-term it improves
the patient’s quality of life, but also gives side effects and motor impairment after many
years of use. A transport of TH to the brain is expected to naturally increase the amount
of L-DOPA and dopamine if L-tyrosine and the cofactor tetrahydrobiopterin are present.
This was the envisioned ERT in this project. The NPs were selected based on their
ability to absorb large amounts of protein, to cross an in vitro model of the blood-brain
barrier and because they consist mainly of cross-linked maltodextrin, a biodegradable
polymer. TH used in this study was recombinant human enzyme, and we found that
expression of TH in a fusion protein with a ZZ-carrier as a partner protein, provided a
homogeneous, active enzyme at high yield. The binding between TH and the NPs was
investigated by atomic force microscopy, size determination using dynamic light scattering
and size exclusion chromotography. The changes in enzymatic activity of TH during a 24
hours time-lapse, were measured by an assay using radioactively labelled tyrosine, and the
uptake of NP-bound TH into cells was evaluated by confocal microscopy. TH was found to
be absorbed into the pores of the NPs upon titration with increasing concentration of TH,
which showed a small but steady increase in the size of the NPs, as well as a phase change
upon atomic force microscopy visualisation. TH’s enzymatic activity was initially reduced
by the NPs, but on the long run stabilised by them, and even further stabilisation was
obtained in the presence of oxidative protecting enzymes or when inhibited by dopamine.
Confocal imaging of TH with a fluorescent label, showed that all four different cell types
that were tested, could take up TH only when it was bound to NPs. These results show
the potential of these NPs to deliver TH and their potential application for ERT.
Front figure: PC12 cells were incubated with Alexa Fluor 568 labelled tyrosine hydroxylase (red) and of
which the nuclei had been stained with 4,6-diamindino-2-phenylindole (blue) before imaging with Leica
TCS SP5, a confocal microscope.
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Oppsumering
Ma˚let med denne masteroppgaven har vært a˚ karakterisere nanopartikler som tyrosin
hydroksylase har blitt bundet til, for a˚ kunne evaluere om de kunne brukes til en en-
zymerstatningsterapi for Parkinson’s sykdom. Tyrosin hydroxylase er et enzym som
katalyserer den hastighetsbestemmende reaksjonen i syntesen av katekolaminene som er
en viktig gruppe innenfor nevrotransmittere. Det katalyserer L-tyrosin fra kosten til L-
3,4-dihydroksyfenylalanin. Niv˚aet av dopamin, en av katekolaminene, er lavt i hjernen
til Parkinsons pasienter. Typisk behandling er tilførsel av L-3,4-dihydroksyfenylalanin,
som ved siden av en positiv innvirking p˚a pasientenes liv, ogs˚a har bivirkninger og gir
problemer med motorikken etter langvarig bruk. Ved a˚ transportere tyrosin hydroksy-
lase til hjernen, kan niv˚aet av b˚ade L-3,4-dihydroksyfenylalanin og dopamin økes p˚a en
naturlig m˚ate, dersom kofaktoren tetrahydrobiopterin og L-tyrosin er tilstede. Dette
var i sikte da ideen om enzymerstatningsterapi ble utarbeidet. Nanopartiklene ble valgt
ut ifra deres egenskap til a˚ kunne absorbere store mengder protein, krysse en in vitro
model av blod-hjerne barrieren og fordi de er laget av polymerisert maltodekstrin som
er bionedbrytbart. Bindingen mellom tyrosin hydroksylase og nanopartiklene ble studert
ved hjelp av atomkraftmikroskop og størrelsesm˚alinger med dynamisk lysspredning og
gelfiltreringskromotografi. Endringene i enzymaktiviteten til tyrosin hydroksylase over en
24 timers periode ble m˚alt med radioaktiv str˚aling, og opptaket av nanopartikkelbundet
tyrosin hydroksylase i celler ble evaluert i konfokalmikroskopet. Tyrosin hydroksylase var
i dette prosjektet rekombinant humant enzym og vi fant ut at uttrykking av tyrosin hy-
droksylase som et fusjonsprotein sammen med et annet protein gav et homogent og aktiv
enzym med høyest avkastning. Det ble funnet ut at nanopartiklene absorberer tyrosin hy-
droxylase ved observasjonen av en liten, men gjevn økning i nanopartikkelstørrelse under
en konsentrasjontitrering av tyrosin hydroksylase. Tyrosin hydroksylases enzymaktivitet
ble først redusert av nanopartiklene, men i det lange løpet stabilisert av dem og enda mer
stabilisering ble oppn˚add n˚ar enzymer som beskytter det oksidative miljøet var tilstede
eller n˚ar tyrosin hydroksylase ble hemmet av dopamin. Konfokalbilder som ble tatt av
fluorescerende tyrosin hydroksylase viser at all fire celletypene som ble testet kunne ta
opp enzymet, men kun n˚ar det var bundet til en av nanopartiklene. Disse resultatene
viser potensiale som disse nanopartiklene har til a˚ levere tyrosin hydroksylase til hjernen
og deres bruk i en enzymerstatningsterapi.
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1 Introduction
1.1 Nanomedicine in drug delivery
Nanotechnology is used in an increasing number of areas of both industry and research.
In medicine for example, nano-scaled carrier devices can be loaded with drugs to improve
the pharmaceutical effect. Before nanotechnology became integrated in the development
of pharmaceutics, drugs have been selected by two distinguished properties: their phar-
maceutical action and their targeting abilities. Many potential drugs are rejected because
they lack the ability to selectively accumulate in the organ or cell type of interest and
can therefore not ensure their own delivery to the correct site. The separation of these
properties into a drug substance and a carrier substance revolutionises the ideas about
how to develop new treatments [1] and shows the huge potential of nanotechnology in
medicine.
Nanocarriers are usually nanoparticles (NPs) that can transport the drug to a certain
tissue or organ in the body like the brain [2, 3, 4, 5] and even to specific cells with an
identifiable receptor on their surface. In the latter case, the nanoacarrier should contain
the right antibody against its specific receptor. Nanocarriers could also include other
systems, for example are nanotubes used [6]. Advances are made in sub-cellular targeting
of the drug by the help of nanocarriers which directs the drug to a predetermined site
within the cell [1].
Specific targeting by recognition of the nanocarrier by a receptor is in general obtained
by modifying NPs at their surface. The recognition will then hopefully be proceeded by
internalisation of the NP, usually by endocytosis - a process where the membrane deforms
into small balls called endosomes, including the external substance at their inside. The fate
of the NP will then differ according to the type of particle and its surface modifications.
1.2 Medication to the brain - the blood-brain
barrier (BBB)
The brain is the most important organ in our body and is therefore well protected. It
has its own immune system and the ways in and out, through which nutrients and other
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physiological important molecules flow, are tightly regulated. Only few pharmaceutics
are therefore able to treat the brain. Several membranes separate the brain from the rest
of the body. One of them is the blood-brain barrier (BBB) which has to be crossed by
medicaments in order to enter the brain. There also exist different administration routes
for drugs targeting the brain like the nasal pathway. Hitherto the BBB seems the most
effective way for delivery of drugs to the brain [7]. Almost all neurons in the brain are
in contact with a capillary blood vessel. The effectiveness is also reflected in the huge
surface area of the BBB compared to the other barriers.
1.2.1 Physiology of the BBB
The BBB consists of a membrane of both blood vessel cells and brain cells, usually of the
type called astrocytes (Figure 1.1). A layer of tightly packed endothelial cells make up
the blood vessel wall of all the small capillaries nourishing the brain. The structure of
these capillaries differs from those in the rest of the body by not having an inter-cellular
passage between the cells. The cells make up a nice layer by having tight junctions almost
gluing them together. The side of the endothelial cells that does not face the blood is
approximately 96% covered with end-feet from mainly astrocytes. Astrocytes are glial
cells situated between neurons also called nerve cells, in the brain [8]. In contrast to
neurons, they do not conduct any nerve signal.
Figure 1.1: The blood-brain barrier and mechanisms for transport across it. Reprinted with permission
from Macmillan Publishers Ltd: Nature Reviews Neuroscience [9], copyright (2006).
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1.2.2 Nanoparticles for transport across the BBB
The transport in and out of the brain is heavily controlled [7]. Six different transport
mechanisms across the BBB are known: passive diffusion and the five pathways illustrated
in figure 1.1. The nanocarriers are most likely to be transported by either the receptor-
mediated or the adsorptive transcytosis [10, 11]. The big size of the nanocarriers prevents
it from using passive diffusion which usually only works for small hydrophobic molecules.
The para-cellular aqueous pathway and the trans-cellular lipophilic pathway are reserved
for hydrophilic or hydrophobic molecules, respectively, whereas transport proteins can
only be used by specific molecules like nutrients and signal molecules.
The typical administration route to the brain is through the blood before crossing the
BBB. The phagocytes, a type of white blood cell, could easily degrade the foreign NPs
in the blood. This process is facilitated by opsonisation which is the binding of opsonine
proteins that mark the NPs for this preliminary degradation [12]. NPs must therefore be
designed in order not to be recognised by opsonins.
Another issue to address is the toxicology of the NPs. NPs for use in treatments should
be biodegradable and not toxic to the patient. The degradation of the NPs after they
have performed their pharmaceutical action, must be ensured to avoid undesired effects.
Many NPs are therefore made of biologically degradable polymers like the well-studied
polylactide-co-glycolide (PLGA) or the less known gelatin, chitosan or maltodextrin [13].
It is therefore easy for the body to take all parts from each other and degrade each
substance by itself.
1.3 Parkinson’s disease
Parkinson’s disease (PD) is characterized by cell-death in a part of the middle brain
called substantia nigra. Neurons in this brain area are responsible for the biosynthe-
sis of dopamine, and their specific death results in a decrease of dopamine levels. Since
dopamine is a crucial neurotransmitter for the circuit of information flow for motoric abil-
ities, a progressive movement disorder including the well-known tremor is characteristic
of PD [8].
The typical treatment of PD is symptomatic and aims at increasing the dopamine
levels by oral supply of dopamine through the dopamine precursor L-3,4-dihydroxyphe-
nylalanine (L-DOPA) [14]. The overall effect of the treatment is positive, as patients
experience an improved quality of life and a reduced mortality rate. L-DOPA remains
therefore the standard to which all new treatments are compared [15].
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On the long run there are side effects and lower responsiveness to L-DOPA. Long
term use of levodopa implies the development of motor complications and alternative
treatments are therefore investigated. Cell transplants and gene therapy focus more on
the delivery of dopamine in a more physiological manner [16]. The alternative treatment
envisioned in this master’s project, is the use of enzyme replacement therapy to deliver
the enzyme tyrosine hydroxylase to the brain for the biosynthesis of dopamine.
1.4 The tyrosine hydroxylase enzyme system
1.4.1 Tyrosine hydroxylase
Tyrosine hydroxylase (TH) is an important enzyme only expressed in a few organs. It
catalyses the conversion of the amino acid L-tyrosine to L-DOPA (Figure 1.2) which can
be further metabolised to the catecholamines dopamine, noradrenaline and adrenaline.
The catecholamines are an important group of neurotransmitters in the central nervous
system. Neurotransmitters are molecules that transfer an electrical signal coming along
the axon of neurons to a chemical signal. They cross the synaptical cleft, which is a
small space between two neurons, to transfer the signal. In this way the next neuron can
receive and carry on the signal along its own axons. TH is the enzyme catalysing the rate
limiting step in the catecholamine biosynthesis (Figure 1.2).
Figure 1.2: The biosynthesis of dopamine. The first step converses dietary L-tyrosine to L-3,4-
dihydroxyphenylalanine (L-DOPA) and is catalysed by tyrosine hydroxylase (TH). The second step
converses L-DOPA to dopamine and is catalysed by DOPA decarboxylase (DDC).
1.4.2 Aromatic amino acid hydroxylase family
TH, phenylalanine hydroxylase (PAH) and the tryptophan hydroxylases (TPH1 and
TPH2) are all part of the aromatic amino acid hydroxylase (AAAH) family. They are
similar in both primary structure (Figure 1.3), quaternary structure (Figure 1.4) and
function.
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Figure 1.3: Sequence alignment of the aromatic amino acid hydroxylases (AAAHs) human tryptophan
hydroxylase 1 and 2 (HTPH1 and HTPH2), human phenylalanine hydroxylase (HPAH) and human
tyrosine hydroxylase 1 (HTH1) [17]. The asterisks above the sequence indicate identical amino acids
at this position and the dots indicate the degree of similarity between the amino acid sequences of the
AAAHs.
The monomers, which are the subunits of the enzymes, consist of three domains:
first the regulatory domain at the amino terminus, in the middle the catalytic domain
and at last the polymerisation domain at the carboxyl-terminus (Figure 1.4). X-ray
diffraction derived crystal structures are known for the latter two domains, whereas the
amino terminal’s regulatory domain is flexible and has so far failed to crystallise. The
monomers are very similar in primary structure, that is the amino acid sequence, especially
at the catalytic domain where the amino acid substrate binds to become hydroxylated. As
in TPH1 and TPH2 human TH is a homotetramer (Figure 1.4), containing four identical
subunits and so are the TPHs, whereas PAH can be a dimer or tetramer.
Each AAAH catalyses the incorporation of an -OH group on an aromatic amino acid
14
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Figure 1.4: Cartoon representations of the structure human tyrosine hydroxylase where the iron in each
subunit is shown as a black sphere. The crystal structure is determined by X-ray crystallography and
found in the protein data bank (PDB). (a) Side view of a monomer where the amino terminus regulatory
domain (blue) is derived from crystal structures of human TH (PDB-ID 2XSN; non published results)
and the catalytic domain (orange) and the oligomerisation domain (red) containing the carboxyl terminus
is derived from rat PAH (PDB-ID 2phm; [18]). (b) Side view of the tetrameric structure of the biological
assembly of TH with each monomer in its own colour (PDB-ID 2xsn). This structure is similar to the
structure from the rat enzyme (PDB-ID 1TOH; [19]). (c) Top view of the monomer. (d) Top view of the
tetramer. The monomers are oriented the same way as the pink subunit of the tetramer. The images
were generated by PyMOL (Schro¨dinger).
15
Introduction
using molecular oxygen and the cofactor tetrahydrobiopterin (BH4) (Figure 1.5).
Figure 1.5: The mechanism for the aromatic amino acid hydroxylases including the regenera-
tion of the cofactor tetrahydrobiopterin (BH4). 4 a−BH4 = BH4-4a-carbinolamine; 5-OH-Trp =
5-hydroxytryptophan; DHBR = dihydropteridine reductase; L-Phe = L-phenylalanine; L-Trp =
tryptophan; L-Tyr = L-tyrosine; PCD = pterin-4a-carbinolamine dehydratase; qBH2 = quinoid-
dihydrobiopterin. Figure modified from [20] and [21].
1.4.3 The cofactor tetrahydrobiopterin
BH4 is the cofactor for all the AAAHs. It is converted to tetrahydrobiopterin-4a-carbinol-
amine (4a-BH4) and further to quinoid-dihydrobiopterin (qBH2) during the reaction catal-
ysed by TH (Figure 1.5). BH4 competes with the catecholamines which bind to the active
site and inhibit the enzymatic activity of TH. This end product inhibition will regulate the
production of catecholamines in synergy with cyclic adenosine mono phosphate (AMP)-
dependent phosphorylation, a modification that releases the catecholamine inhibition [22].
No further biosynthesis is needed when there are high concentrations of dopamine and
other final catecholamine products that then will bind and inhibit TH.
1.4.4 The non-heme iron II ion
Each TH-monomer coordinates an iron II ion (Fe2+) at the catalytic site. The iron is
coordinated by three amino acid residues and one to three water molecules [23]. The iron
must be protected from oxidation, as it is easily converted to catalytically inactive Fe3+.
Antioxidants and enzymes responsible for the redox balanced environment of the cell can
therefore stabilise TH and preserve the enzymatic activity by ensuring the right oxidation
state of iron, like is known for PAH [24].
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1.4.5 Inherent instability
TH is a protein that is difficult to work with in the lab. It has an inherent instability, as
its catalytic activity is easily inactivated and it readily aggregates [25]. Aggregates are
large complexes of macromolecules that can no longer be kept in solution, aggregation
is a non-reversible reaction that in vivo can result in cell death. TH is sensitive to the
contents of the solution it is dissolved in, as it needs a relatively crowded and redox
balanced environment to avoid its tendency to aggregate.
1.4.6 Enzyme replacement therapy
Enzyme replacement therapy (ERT) is a strategy to deliver the enzyme in its functional
form to the site where it is needed to carry out its activity. This therapeutic approach is
being increasingly used for the treatment of genetic disorders like the rare Fabry disease
[26] or Gaucher disease [27]. We have envisioned that such a therapy could be developed
with TH for Parkinson’s disease and this is the final aim of the work carried out in this
Master’s thesis. The ERT with TH might also be useful for related diseases where a
mutation in the gene for TH causes a TH deficiency [28].
1.5 Purpose
It is expected that the levels of dopamine will increase when providing TH in its functional
form to the brain. This assumes that the substrate L-tyrosine and the cofactor BH4 are
already present. The goal of this master project is to contribute to the development of an
ERT for PD or related diseases which uses catalytic NPs showing high enzymatic activity
and stability. The main objective of this work is to obtain functionalised NPs with TH
bound, that are able to enter cells. The NPs NP+ and DPPGNP+ will be evaluated for
their potential as carriers of TH by investigation of their characteristics.
Another important purpose of this work is both to gain competence in the different
experimental methods that can be used to study proteins and/or NPs and to acquire
knowledge about the well-established scientific field of TH and the use of NPs in medical
research.
1.5.1 Specific aims
Three subprojects have been defined with the following specific aims:
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1. To probe the binding between the NPs and TH.
2. To evaluate the changes in TH activity upon binding.
3. To investigate if the NPs can deliver TH to cells.
1.5.2 Choice of methods
The first aim will be addressed by using dynamic light scattering (DLS) and atomic force
microscopy (AFM) to determine the size and surface structure respectively, complemented
with size exclusion chromatography (SEC). Enzyme activity is measured by a radioactive
assay with tritium-labelled tyrosine to see if TH preserves its function upon binding to
the NPs as stated in the second aim. The last aim will require cell culture experiments
and imaging with confocal microscopy.
1.5.3 Hypotheses
The NPs that will be used in the work of this master’s thesis are known to be porous and
positively charged [29] and are therefore expected to bind the slightly negatively charged
TH, at neutral pH TH’s isoelectric point (pI) is 6.11. The binding is hypothesised to rely
on weak intermolecular interactions and based on previous studies on the binding of TH
to liposomes it is expected that the enzyme will bind through the regulatory domain [30],
so that the catalytic activity will be maintained.
However, TH could loose its enzymatic activity if its conformation is altered too much.
Since there is no covalent bond expected between the NP and TH, the conformation is
expected to be only slightly modified upon binding.
The selected NPs are shown to deliver other proteins successfully to cells [31]. TH is
therefore also expected to be delivered.
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considerations
2.1 Theoretical considerations
2.1.1 Tyrosine hydroxylase
TH is similar in sequence of amino acids (AAs), the protein’s primary structure to both
PAH and the TPHs as they all are part of the AAAH enzyme family (Figure 1.3). The
sequence identity is greater than 80% in the catalytic domain [32]. The crystal structure
for the sequence from amino acid 193 and to the carboxyl terminus is known for the
human TH (Figure 1.4). The amino-terminus is mobile and the structure is not known
yet.
TH that I have worked with is splicing isoform 1 (SWISS-PROT ID P07101) and is
presented in the sequence alignment (Figure 1.3). The AAs 31 to 61 are missing compared
to isoform 3 due to alternative splicing (not shown). The total length is therefore 497
AAs and the molecular weight 55 612 Da. The theoretical diameter can be calculated by
measuring the longest distance in the crystal structure that is known (Figure 1.4d). When
this is done in Discovery (Accelerys), the calculated diameter is 11.9 nm. The regulatory
domain at the amino terminus is for PAH located on top of the tetramer [18] and this can
reasonable be expected for TH as well. The diameter will therefore not increase by the
presence of the regulatory domain, but just give the structure a more spherical appearance
instead of a slightly flat square.
2.1.2 The nanoparticle system
There are two types of NPs (Figure 2.1) that have been selected for the work presented in
this thesis [29]. They are called NP+ and DPPGNP+. Both consist mainly of maltodex-
trin - an oligomer of glucose and is thus a sugar compound which can easily be degraded
biologically. During the synthesis the maltodextrin is cross linked giving a polysaccharide
and porous particle [33]. The particles are positively charged due to the incorporation
of the cationic ligand glycidyltrimethylammonium (GTMA) which can aid protein ab-
sorption. DPPGNP+ are in addition functionalised with dipalmitoylphosphatidylglycerol
19
Theoretical and methodological considerations
(DPPG) which is a lipid giving more rigidity to the structure as it is expected to fill the
core of the porous particles.
Figure 2.1: The nanoparticles NP+ (left) and DPPGNP+ (right). The maltodextrin polymer gives the
porous structure (black and white), whereas the positive surface charge (red) is due to the GTMA. The
inner charge (yellow) of GTMA is cancelled out by the lipid core of DPPG (blue) for the biggest particle.
TH is shown to scale (many colours) and the scale bar is 10 nm.
The NPs behave as sponges and absorb high amounts of protein or lipid [29]. If
assuming spherical shape for TH, there will be 25 THs per NP if the weight to weight
ratio is 1:1. Nanoparticles, when present in the blood, are often quickly detected by
opsonins which are proteins that mark a foreign substance so that it can be degraded.
By loading and saturating the cationic NPs with negatively charged sustances like the
protein of interest, in this case TH, the opsonation is inhibited and the NPs have a longer
circulation time in the blood [29].
It has also been observed that NP+ are transcytosed across a cellular model of the
BBB, whereas the same experiment for DGGPNP+ was inconclusive due to difficulties
in the procedure [34]. These NPs seem therefore a suitable choice to be tested as a
nanocarrier of TH for ERT in Parkinson’s disease and related malignancies.
It is important to know the NPs toxicology because if the NPs are to be used for human
administration, then they should not impair a danger on the patient. The toxicology of
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NP+ has been studied in detail, showing no apparent damage on cells or on DNA except
at very high doses [35] which would not occur in vivo.
2.2 Methodological considerations
Here I will only present the non-typical methods that have been used. Please continue to
the methods chapter for the details on the standard biochemical methods as recombinant
protein expression and purification, gel electrophoresis and chromatography.
2.2.1 Dynamic light scattering
DLS is a method for size determination of small particles in suspension in the nanometre
range, including proteins. A monochromatic laser light is shown through the solution con-
taining the suspended particles and the refracted laser light intensity pattern is recorded
at a certain angle (Figure 2.2). The pattern changes over time according to rate of dif-
fusion of particles in solution. Small particles will move fast and give a fast changing
intensity pattern, whereas larger particles will diffuse slower through the medium and
give a less changing intensity pattern. The intensity patterns are compared over time
giving a correlation function (Figure 2.2). The rate of diffusion is determined by the
correlation function.
Figure 2.2: The principle of dynamic light scattering [36].
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The particles’ radius can then be calculated by the Einstein-Stokes relation (equation
2.1) where D: rate of diffusion, T : temperature, η: viscosity of solution and R: particle
radius.
D =
kT
6piηR
(2.1)
DLS works well for particles that easily scatter the laser beam, meaning that their
refractive index is different from the medium in which they are suspended. In addi-
tion the particles are assumed to refract the beam indifferent of their orientation which
means that they have to be spherical, so for non-spherical particles the radius will be
less exact. Another challenge is that samples should be a homogeneous suspension and
no sedimentation should occur during the measurement. The movement will then not be
random diffusion and no longer only depend on the size. In addition, the sample should
be uniformly distributed, containing only particles of the same size as it is not possible
to distinguish between types of particles by DLS. Neither should the samples contain
aggregates, dust or other contaminations as big particles of course scatter the laser beam
much more efficiently than small particles, giving an unnatural proportion of big versus
small particles.
2.2.2 Atomic force microscopy
AFM is a high resolution imaging method where a cantilever with a small tip scans over
the sample surface and is deflected by the intermolecular forces. There exist different
modes depending if the tip is in the range of repulsive forces that dominate in the closest
region above the surface or in the range of attractive forces (Figure 2.3a). Tapping mode
makes the cantilever arm vibrate so that both regions are covered. While the cantilever
scans over the surface and is deflected up and down according to the surface structure and
composition, the laser beam will be reflected with a smaller and bigger angle according
to the deflection. The changes in the laser beam reflection angle are detected by a photo
diode for each position of the cantilever tip (Figure 2.3b). In this way the result for each
point is visualised as one pixel.
AFM images show three different modes of the same picture: Height, amplitude and
phase. The height image mode represents the sample surface’s topography. The imaging
was done in tapping mode, therefore the tip vibrates at a specific frequency. These
vibrations have an amplitude and phase, just like all other waves, which change according
to the forces exerted on the tip by the sample surface. The amplitude and the phase
retrace show the variations in the amplitude and phase of the tip vibration, respectively.
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Figure 2.3: The principle of atomic force microscopy. (a) The force between the tip and the sample
surface changes with the distance between them [37]. (b) The laser light is deflected when the cantilever
arm is deflected due to a change in the force between the tip and the sample surface [38].
AFM works very fine for inorganic samples with a hard surface. Changes in the
surface’s structure or composition can then be seen in either of the images. Sometimes
the AFM’s high resolution is also needed for biological samples having a soft surface. The
imaging procedure is then much more difficult as the cantilever tip can scrape into the
sample surface or parts of the sample can stick to the tip and be moved around interfering
with the scanning.
AFM devices can be grouped in two categories, one for imaging and one for force
measurements between tip and sample. The AFM instrument that has been used for the
work presented in this thesis is best suited for force measurements. The quality of the
images taken is therefore not the best.
2.2.3 Confocal microscopy
Confocal microscopy is a combination of old fashioned light microscopy where the light
is focussed onto the sample and fluorescence microscopy where the sample is fluorescent.
Fluorescence is a property of certain chemical substances that have the ability to emit light
with high intensity at a specific wavelength when excited by light of a shorter wavelength.
To obtain a high resolution, the laser light is focussed as a spot onto the sample which
then illuminates only a small part of the sample. The spot is then scanned over the sample
surface to give an image of the whole sample. At each point some parts of the sample
will get excited and emit light of a lower wavelength, e.g. when green laser light is used
for excitation, red light is emitted (Figure 2.4). The emitted light is detected, recorded
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and shown on a computer screen.
Figure 2.4: The principle of confocal microscopy [39].
Usually several laser lights are used to excite each their specific fluorescent substance
in the sample. Resolution for a 63x oil immersion objective with numerical aperture 1.4
is 0.24 µm for green light. Oil immersion is to avoid a refraction and therefore loss of
info at the interface of two media. Since objectives with a high numerical aperture due
to their high magnification have a very limited depth of field, the sample is easily moved
out of focus. 3-D pictures can be obtained by moving the sample through the focal plane
of the lenses.
Resolution is still limited by diffraction of the light waves which again depends on
the wavelength. To increase the resolution, the wavelength has to be shortened, which
for example is obtained when using electrons instead of UV or visible light as done in
electron microscopy. Another challenge is that the sample needs to be fluorescent. Not
all features in a sample can become fluorescent although this can both be obtained by
covalent binding to a fluorescent dye by the use of fluorescent antibodies or through fusion
to a fluorescent protein.
2.2.4 Tyrosine hydroxylase activity assay
The TH enzymatic activity was measured by a radioactive assay using tritated tyrosine,
for details see methods section 4.6. To ensure the availability of BH4 and to avoid the
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accumulation of its oxidised forms, BH4 is kept reduced by the presence of the reducing
agent dithiothreitol (DTT) in the assay. DTT in this way substitutes the enzymes that
in vivo catalyse the steps back to the reduced form of BH4 (Figure 1.5) [21] .
The experiments were only performed in two parallels because the timing is crucial
for the assay’s accuracy and reproducibility. Proper statistics for each experiment could
therefore not be performed because the standard deviation is calculated from only two
parallels. However, experiments were performed several times at slightly different condi-
tions, so the trends that the graphs presented show, are representative.
Before starting the work with radioactivity, I took the internal training course of the
University of Bergen in radiation protection and use of ionising radiation.
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3.1 Instruments
Method Instrument Provider
Atomic force microscopy Molecular force probe 3D Asylum Research
Concentration measurements Nanodrop ND-1000 Saveen Werner
Centrifugation Centrifuge 5810R Eppendorf
Dynamic light scattering Nanosizer Z Malvern Nordic
Cell culture (incubator) Heraeus Hera Cell 150 Tamro Medlab
Bacteria culture Excella E24 Incubator Shaker New Brunswick Scientific
Liquid scintillation analyzer Tri-carb 2900TR Packard
Size exclusion chromatography Biologic duoflow BioRad-Laboratories
3.2 Nanoparticles
Name Provider
Nanoparticles of maltodextrin (NP+) D. Betbeder (gift)
Nanoparticles of maltodextrin
and dipalmitoylphosphatidylglycerol (DPPGNP+) D. Betbeder (gift)
Fluorescent DPPGNP+ which are labelled with
dioctadecyl tetramethylindocarbocyanine perchlorate (DiI)) D. Betbeder (gift)
Gold nanoparticles coated with MUA (Au-MUA) Wilhelm Glomm (gift)
3.3 Enzymes
Name Provider
Acc651 New England Biolabs
AmpliTaq Gold Applied Biosystems
Catalase bovine liver, lyophilized powder Sigma Aldrich
Nco1 New England Biolabs
Restriction protease factor Xa Boehringer-Mannheim
Superoxide dismutase (SOD) from bovine erythrocytes Sigma Aldrich
Taq DNA polymerase England Biolabs Inc.
Tobacco etch virus (TEV) protease Gu¨nther Stier (gift)
T4 DNA ligase Fermentas
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3.4 Cell lines and bacteria
Name Provider
16HBE14o- (human bronchial epithelial cell line) Customary cell line in
the lab of D. Betbeder
Escherichia coli strain BL21-CodonPlus(DE3)RIL Stratagene
Escherichia coli XL10-Gold ultracompetent cells Stratagene
HEK293 (human embryonic kidney cell line) Eystein Oveland (gift)
NCI-H292 (human epithelial cell line) Customary cell line in
the lab of D. Betbeder
PC12 (cell line derived from rat pheochromocytoma) Originally a gift from Stein
Ove Døskeland, now a
customary cell line at
Aurora Martinez’s lab
3.5 Medium and cell equipment
Name Provider
4-well plates Nunc
8-well Lab-Tek chamber slides Thermo Scientific
Bovine serum Sigma Aldrich
Dulbecco’s modified Eagle’s medium (DMEM) Sigma Aldrich
Fetal bovine serum (FBS) Sigma Aldrich
Horse serum Invitrogen
Prolong Gold with DAPI antifading reagent Life technologies
Roswell Park Memorial Institute (RPMI) medium Sigma Aldrich
3.6 Chemicals
Name Provider
4’,6-diamidino-2-phenylindole (DAPI) Invitrogen
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES) Sigma Aldrich
Acetic acid (CH3COOH) Sigma Aldrich
Adenosine 3’-5’-cyclic monophosphate Sigma Aldrich
Agar-agar Merck
Agarose Sigma Aldrich
α-lactose Sigma Aldrich
Ammonium iron (II) sulphate hexahydrate
((NH4)2Fe(SO4)2 · H2O) Sigma Aldrich
Ammonium sulfate ((NH4)2SO4) Sigma Aldrich
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Name Provider
Blue dextran Sigma Aldrich
Bromophenol Blue Merck
Charcoal activated Merck
Compound III (3-amino-2-benzyl-7-nitro-4-
(2-quinolyl)-1,2-dihydroisoquinolin-1-one) Maybridge Ltd.
Coomassie brilliant blue R-250 Bio-Rad
Cytochrom c Sigma Aldrich
Deoxynucleotriphosphates mix, 10 mM (dNTPs) Invitrogen
Distilled water Milli-Q
Dimethyl sulfoxide (DMSO) Sigma Aldrich
Dopamine Sigma Aldrich
Dithiothreitol (DTT) Sigma Aldrich
Ethanol Sigma Aldrich
Ethylenediaminetetraacetic acid (EDTA) Sigma Aldrich
Fluorescein isothiocyanate (FITC) Sigma Aldrich
GelRed Nucleic Acid Stain Biotium
Glutamine (Gln) Sigma Aldrich
Glycerol Merck
Glucose Sigma Aldrich
Hydrogen chloride (HCl) VWR International
Imidazole Sigma Aldrich
Isopropanol Sigma Aldrich
Isopropyl thiogalactoside (IPTG) Sigma Aldrich
LSC-cocktail Emulsifier-safe PerkinElmer
L-[3,5-3H]-tyrosine (tritium-labelled) GE Healthcare
L-Tyrosine Sigma Aldrich
Kanamycin Sigma Aldrich
Magnesium dichloride (MgCl2) Applied Biosystems
Magnesium sulfate (MgSO4) Sigma Aldrich
Paraformaldehyde (PFA) Fluka
Pefabloc SC PLUS Roche
Penicilin Invitrogen
Penicilin and streptomycin mix, 100 x Sigma Aldrich
Pepstatin A, microbial Sigma Aldrich
Peptone from casein, pancreatic digest Sigma Aldrich
Phenylmethanesulfonylfluoride (PMSF) Sigma Aldrich
Phosphate buffer saline tablets Sigma Aldrich
Poly-L-lysine Roche
Potassium chloride (KCl) VWR International
Potassium phosphate monobasic (KH2PO4) VWR International
PSC-Protector solution Roche
Sodium bicarbonate (NaHCO3) Sigma Aldrich
Sodium carbonate (Na2CO3) Sigma Aldrich
Sodium chloride (NaCl) Sigma Aldrich
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Name Provider
Sodium dodecyl sulfate (SDS) Sigma Aldrich
Sodium phosphate dibasic dihydrate
(Na2HPO4 · 2 H2O) Sigma Aldrich
Streptomycin Invitrogen
Tetrahydrobiopterin (BH4) Schircks Laboratories
Trizma base primary standard and buffer (Tris-HCl) Sigma Aldrich
Trypsin Biochrom
Trypsin –EDTA solution Sigma Aldrich
Tryptone Sigma Aldrich
3.7 Other products
Product name Provider
Alexa Fluor 568 Protein Labeling Kit Molecular Probes
Amersham Biosciences PD-10 desalting column GE Healthcare
GeneRuler 1 kb DNA ladder Fermentas
HiLoad Superdex prep grade Column GE Healthcare
NEBuffer 3 10 x New England Biolabs
PCR Gold buffer 10 x Applied Biosystems
pETZZ-1a plasmid Gu¨nther Stier (gift)
PureYield TM Plamid MidiprepSystem Promega
TALON Superflow Metal Affinity Resin Clontech Laboratories
ThermoPol Buffer 10x Pall Life Sciences
QIAquick gel extraction kit Qiagen
QIA PCR purification kit Qiagen
Yeast extract nitrogen base without amino acids Sigma Aldrich
3.8 Buffers and solutions
3.8.1 Autoinduction medium
The autoinduction medium is made as a combination of the following mixtures:
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Name Final concentration Chemical Molecular weight Amount
ZY 1.08 % (w/v) Tryptone – 10 g
0.54 % (w/v) Yeast extract – 5 g
– Water – 925 ml
NPS 0.5 M (NH4)2SO4 132.14 g/mol 6.6 g
1 M KH2PO4 136.09 g/mol 13.6 g
1 M Na2HPO4 · 2 H2O 141.96 g/mol 17.8 g
– Water – 90 ml
5052 0.5% (w/v) Glycerol 92.09 g/mol 25 g
0.05% (w/v) Glucose 180.16 g/mol 2.5 g
0.2% (w/v) α-lactose 342.30 g/mol 10 g
– Water – 73 ml
MgSO4 1 M MgSO4 · 7 H2O 246.47 g/mol 24.65 g
– Water – 100 ml
5052 is heated in the microwave in order to dissolve the lactose. All the mixtures are
autoclaved individually and mixed as follows:
Volume Mixture
928 ml ZY
50 ml NPS
20 ml 5052
2 ml 1 M MgSO4
This gives the following final concentrations:
Final concentration Chemical
1% (w/v) Tryptone
0.5% (w/v) Yeast extract
0.5 M (NH4)2SO4
1 M KH2PO4
1 M Na2HPO4 · 2 H2O
0.5% (w/v) Glycerol
0.05% (w/v) Glucose
0.2% (w/v) α-lactose
2 mM MgSO4 · 7 H20
3.8.2 Complete Dulbecco’s modified Eagle’s medium
Final concentration Chemical Initial concentration Volume
– DMEM – 500 ml
10% (v/v) FBS 100% 55 ml
2 mM Glutamine 226 mM 5 ml
1 x Penicilin/Streptomycin mix 100 x 5 ml
New glutamine was added every 3 weeks to prevent a lower concentration due to
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spontanous deamination. In the lab of Prof. Didier Betbeder, the antibiotics were added
separately with final concentration of 100 U/ml penicilin and 100 µg/ml streptomycin.
3.8.3 Complete Roswell Park Memorial Institute medium
Final concentration Chemical Initial concentration Volume
– RPMI – 500 ml
10% (v/v) Horse serum 100% 55 ml
10% (v/v) Bovine serum 100% 55 ml
2 mM Glutamine 226 mM 5 ml
1 x Penicilin/Streptomycin mix 100 x 5 ml
New glutamine was added every 3 weeks to prevent a lower concentration due to
spontanous deamination.
3.8.4 Destaining solution
Final concentration Chemical Initial concentration for 1 l
30% (v/v) EtOH Absolute 300 ml
5% (v/v) Acetic acid 99.8% 50 ml
3.8.5 FPLC buffer
Concentration Chemical Molecular weight (Mw) for 1 l
20 mmol HEPES 238.3 g/mol 4.77 g
200 mM NaCl 58.44 g/mol 11.69 g
The pH is adjusted to 7.0 with 2 M NaOH before all the water is added. The buffer
is filtered, degassed and cooled down to 4◦C.
3.8.6 HEPES buffer
Concentration Chemical Mw (g/mol) for 100 ml
400 mmol HEPES 238.3 9.53 g
The pH is adjusted to 7.0 with 2 M NaOH before all the water is added. Half of it is
diluted 1:20 with water to give a 20 mM buffer.
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3.8.7 Liquid Luria-Bertani (LB) medium
Concentration Chemical Mw (g/mol) for 1 l
– Peptone – 10 g
– Yeast extract – 5 g
171 mM NaCl 58.44 10 g
After the components are mixted, LB medium is autoclaved.
3.8.8 Luria-Bertani agar plates
15 mg agar is added to a liter of liquid Luria Broth (LB) medium to obtain a 1.5% agar
concentration. The mixture is autoclaved and cooled to 55◦C and 20 ml is poured in each
plate in a sterile environment. The plates are dried for 45 min.
3.8.9 4% (w/v) Paraformaldehyde
1 g paraformaldehyde (PFA) is dissolved in 25 ml phosphate buffered saline (PBS) by
continuous stirring at 65◦C and left to cool down.
3.8.10 46 mM Pefabloc solution
Concentration Chemical Mw (g/mol) Amount mixed
46 mM Pefabloc SC Plus 239.7 12.5 mg
8.8 mM HEPES pH 7.0 238.3 500 µl
– PSC-Protector solution – 625 µl
3.8.11 Phosphate buffered saline (PBS)
Concentration Chemical Mw (g/mol) for 1 l
140 mM NaCl 58.44 8.18 g
2.7 mM KCl 75.55 0.20 g
10 mM Na2HPO4 177.99 1.8 g
1.8 mM KH2PO 136.09 0.24 g
The pH is approximately 7.4. Alternatively a phosphate buffer saline tablet is dissolved
in 200 ml by magnetic stirring.
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3.8.12 4 x SDS denaturation buffer
Concentration Chemical Mw (g/mol) for 10 ml
250 M Tris-HCl, pH 6.8 157.60 9.53 g
8% (w/v) SDS 288.38 0.8 g
40% (v/v) Glycerol 92.09 4 ml
75 mM DTT 154.25 0.116 g
0.02% Bromophenol Blue 669.96 0.002 g
SDS denaturation buffer is usually stored in aliquotes of 95 µl without the dithiothre-
itol (DTT) at -20◦C. The DTT is added right before use.
3.8.13 Super optimal broth with catabolite repression (SOC)
medium
Concentration Chemical Initial for 1 l
2% (w/v) Tryptone – 20 g
0.5% (w/v) Yeast extract – 5 g
0.05% (w/v) NaCl 58.44 g/mol 0.5 g
1 M KCl 400 M stock 2.5 ml
20 mM MgCl2 1 M stock 2 ml
20 mM Glucose 1 M stock 2 ml
All components, except the magnesium chloride and the glucose are mixed and the
medium is autoclaved. Right before use magnesium chloride and glucose are added.
3.8.14 Staining solution
0.25 g Coomassie Blue is dissolved in 250 ml destaining solution and all is filtered.
3.8.15 Stop solution
Concentration Chemical Mw (g/mol) for 500 ml
7.5 (w/v) % Charcoal activated 12.01 37.5 g
1 M HCl (aq) 36.46 500 ml
3.8.16 TAE buffer
Concentration Chemical Mw (g/mol) for 1 l
40 mM Tris-HCl 157.60 6.3 g
20 mM Acetic acid 60.05 1.02 g
1 mM EDTA 292.24 0.29 g
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3.8.17 TALON equilibration/wash buffer
Concentration Chemical Mw (g/mol) for 1 l
20 mM Na2HPO4 · 2 H2O 141.96 2.84 g
300 mM NaCl 58.44 17.53 g
1 µg/ml Pepstatin 685.89 0.001 g
3.8.18 Tank buffer
Concentration Chemical Mw (g/mol) for 1 l
19 mM Tris-HCl 157.60 3 g
0.1% SDS 288.38 1 g
156 mM Glycerol 92.09 14.4 g
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4.1 Recombinant tyrosine hydroxylase (TH)
TH was purified following two different novel expression and purification strategies (to be
published). For the first strategy in brief, human TH, isoform 1 (hTH1), was expressed
in Escherichia coli (E. coli) as a fusion protein with maltose binding protein (MBP)
which was cleaved with restriction protease factor Xa at a ratio 1:200; hTH1 was then
further purified by size exclusion chromatography on a HiLoad Superdex column (1.6 cm
x 60 cm; GE Healthcare). The enzyme was up-concentrated by ultrafiltration with filters
with a cut-off of 30 kDa and stored in liquid nitrogen until use. This first procedure was
kindly performed by Ali Javier Mun˜oz Sepulveda, Department of biomedicine, UiB and
the obtained TH was used throughout this thesis unless otherwise stated. The second
strategy was developed during this Master’s work together with Marte Innselset Flydal,
also from the Department of biomedicine and is described in detail below.
4.1.1 TH gene amplification
The TH gene was amplified from 45 and 90 ng DNA template which was the plasmid
vector pMAl-c5x/TH1 containing the TH-MBP gene. The conditions were 1 x GeneAmp
PCR Gold buffer (150 mM Tris-HCl, pH 8.0, 500 mM KCl), 2.5 mM MgCl2, 0.2 mM de-
oxynucleoside triphosphates (dNTPs) and 5 U/µl Amplitaq Gold with 0.2 µM of both the
forward primer (TH-pETZZ-F; 5’-GCTTCCATGGGACCCACCCCCGACGCCA-3’) and
the reverse primer (TH-pETZZ-R; 5’-GCTTGGTACCCAGTGCAGGACCAGGGGA-3’)
in a final volume of 50 µl. The primers were designed such that a Nco1 and an Acc651
restriction site (underlined) were introduced at the start and after the end of the TH
gene, respectively. The polymerase chain reaction (PCR) steps included 2 min at 95◦C, 7
x (20 sec at 95◦C, 20 sec at 54◦C and 2 min at 74◦C) and 20 x (30 sec at 95◦C, 30 sec at
68◦C and 2 min at 72◦C) and a final elongation of 10 min at 72◦C. The size of the PCR
product was evaluated by agarose gel electrophoresis as described below.
4.1.2 Cloning
The PCR products (1549 basepairs) were purified with a Qiagen Purification Kit and cut
with the restriction enzymes Acc561 and Nco1. The conditions during the cutting process
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were 1 x NEBuffer 3 (100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl2, 1 mM DTT, pH
7.9 at 25◦C), 1% (w/v) bovine serum albumin (BSA), 200 U/ml of each Acc651 and Nco1
in a total volume of 50 µl. The samples were incubated 11 hours at 37◦C. Approximately
1 µg of vector pET-ZZ-1a containing a different gene between the Nco1 and the Acc651
restriction sites, was cut in the same way and separated from the ’old’ insert by agarose
gel electrophoresis. The vector fragment was cut out from the agarose gel and purified by
a Qiagen gel extraction kit. The TH gene was cloned into the pET-ZZ-1a vector by T4
DNA ligase in a total volume of 20 µl including 2 µl vector fragment, 15.5 µl cut TH gene,
1 x T4 DNA ligase buffer (40 mM Tris-HCl, 10 mM MgCl2, 10 mM DTT, 0.5 mM ATP,
pH 7.8 at 25◦C) and 0.0625 U/µl T4 DNA ligase. The vector pETZZ-1a/TH thus contains
an open reading frame coding for the fusion protein called ZZ-TH from which TH can be
cleaved at the tobacco etch virus (TEV) protease cleavage site which is situated between
the fusion partner and TH in the fusion protein (Figure 4.1) [40]. The fusion partner
consists of a his-tag at the amino terminus, twice a Z-domain, a synthetic IgG-binding
domain based on staphylococcal protein A [41], and a TEV cleavage site. The his-tag
consists of six histines useful for metal affinity chromatography during the purification
steps. The fusion partner is called a ZZ-carrier because of the double synthetic Z-domain.
Figure 4.1: Scheme of pETZZ-1a vector with the inserted TH gene. Modified from [42]
4.1.3 Vector amplification
E. coli XL10-Gold ultracompetent cells (Stratagene) were transformed with the ligation
mixture containing pETZZ-1a/TH vector as follows: 3 µl of the ligation was added to 37.5
µl of cells, incubated 30 min on ice, 30 sec at 42◦C and 2 min on ice before 400 µl of super
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optimal broth with catabolite repression (SOC) was added. The samples were incubated
45 min at 37◦C and 200 rpm. 50 µl of each sample was plated on Luria-Bertani (LB) agar
plates with 30 µg/ml kanamycin to select for bacteria containing pET-ZZ-1a/TH1. The
LB-plates with cells were incubated upside down at 37◦C overnight. Some of the colonies
were screened directly for the presence of pET-ZZ-1a/hTH1 by colony PCR. In colony
PCR, the bacterial colony is resuspended in a drop of medium and used as a template for
the PCR-reaction. The PCR-reaction contained 1 x ThermoPol buffer (20 mM Tris-HCl,
10 mM (NH4)2SO4, 10 mM KCl, 2 mM MgSO4, 0.1% Triton X-100, pH 8.8 at 25
◦C), 25
U/µl Taq DNA polymerase, 0.2 mM dNTPs and 0.4 mM of each primer (TH-pETZZ-F
and TH-pETZZ-R). The PCR program was initiated by 10 min at 95◦C, followed by 30 x
(30 sec at 95◦C, 30 sec at 55◦C and 2 min at 72◦C) and finished by a final elongation of 2
min at 72◦C. Two colonies containing amplified TH gene were chosen for a 50 ml culture
in liquid LB medium containing 30 µg/ml kanamycin and incubated at 37 ◦C and 200
rpm overnight. 0.7 ml of each bacteria culture was stored in 15% (v/v) glycerol at -80◦C.
From the rest of the bacteria cultures, plasmids were isolated with PureYield TM Plasmid
Midiprep System. The newly isolated plasmids where doublechecked for the presence of
the TH gene by cutting them with the restriction enzymes Acc651 and Nco1 under the
same conditions as previously described. The excision of the TH gene was verified by
agarose gel electrophoresis.
4.1.4 Expression of recombinant TH in Echerichia coli cells
Two 50 µl of E. coli strain BL21-CodonPlus(DE3)RIL competent cells (Stratagene) were
transformed by 1 µl of isolated pET-ZZ-TH plasmid as previously described. The cells
were then plated on LB-medium with 30 µg/ml kanamycin overnight at 37 ◦C. One colony
from each plate was cultured in 25 ml liquid LB-medium with 30 µg/ml kanamycin until
the cell density had reached an optical density at 600 nm of 0.6. The cultures were
then split and recombinant protein production was induced in only one of each culture
by adding isopropyl thiogalactoside (IPTG) to a final concentration of 1 mM. 1 ml was
taken out of each culture after 3.5 hours induction and harvested by centrifugation at 10
000 rpm for 2 min. The bacterial pellet was resuspended in 300 µl of supernatant and the
expression of recombinant TH was evaluated by sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) as described below. A large-scale culture was set up with
600 µl of each uninduced culture in 300 ml autoinduction medium [43] with 100 µg/ml
kanamycin and grown at 37 ◦C an 200 rpm for 2 hours and then at 28 ◦C and 200 rpm
overnight.
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4.1.5 Purification of TH
The big cultures were harvested by centrifugation for 15 min at 4◦C and 4000 rpm in 1 l
tubes, resuspended in a smaller volume and transferred to 50 ml centrifuge tubes. After
a second centrifugation, the bacterial pellets were weighted and frozen at -20◦C until
further use. After thawing, the pellets were resuspended in TALON equilibration/wash
buffer (20 mM Na2HPO4 · 2 H2O, 300 mM NaCl, 1 µg/ml pepstatin) using 10 ml/g pellet.
Phenylmethanesulfonylfluoride (PMSF), a protease inhibitor, in iso-propanol was added
to the dissolved cell pellets to a final concentration of 1 mM before they were sonicated
with 9 sec pulses 3 times for 45 sec with 45 sec of pause in between at 20 output Watts
while kept on ice. The sonicate was centrifuged 30 min at 4◦C and 14 000 rpm to remove
cell debris and insoluble material. The fusion protein ZZ-TH was isolated by metal affinity
chromatography from the crude extract as following. The crude extract was diluted 1:3
with TALON equilibration/wash buffer and applied to an equilibrated column containing
TALON superflow metal affinity resin with a syringe having a filter of 0.45 µm pores.The
flow through was allowed to pass through the column twice. The column was then washed
with equilibrium/wash buffer until the fusion protein was eluted with 150 mM imidazole.
Small samples were taken at each step for evaluation by SDS-PAGE. The buffer was
exchanged on a PD-10 column equilibrated with equilibration/wash buffer to remove
imidazole. Isolated ZZ-TH was cut with tobacco etch virus (TEV) protease (25-27 kDa)
at the optimised conditions of 16 hours at 4◦C at a TEV/ZZ-TH (w/w) ratio of 1:50. The
cut samples were applied to a second TALON column. The flow through and the first
bed volume of the wash were collected, pooled and upconcentrated with amicon filters of
50 kDa cut-off, with FPLC buffer to obtain a sample of purified TH of highest possible
concentration. Here again, small samples of each step were collected and evaluated by
protein concentration measurements and SDS-PAGE. Pefabloc, a protease inhibitor, was
added at a final concentration of 0.5 mM before the sample was stored in liquid nitrogen.
The whole purification procedure was carried out in a cooling room at 4◦C.
4.2 Gel electrophoresis
4.2.1 Agarose gel electrophoresis
To determine the size of a deoxyribose nucleic acid (DNA) fragment, an electrophoresis
was performed on a 10% agarose gel. The 10% (w/v) agarose gel was made by adding 40
ml of TAE buffer to 0.40 g of agarose. The agarose was completely dissolved by heating in
the microwave and left to cool down to approximately 50◦C before 4 µl of GelRed Nucleic
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Acid Stain was added. All was poured into a mold and left to polymerise. 2 µl of 6 x
loading dye was added to 10 µl of each PCR product and loaded onto the wells of the gel.
The electrophoresis was run in TAE buffer at 100 V for approximately 1 hour. The DNA
fragments can be imaged when illuminated by UV light. Pictures were taken of each gel
by a ChemiDoc XRS+ (BioRad) using ImageLab 3.0.1 beta 2 software.
4.2.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis
To determine the presence and the size or the purity and the size of the protein, an SDS-
PAGE was performed on a pre-cast 10% (w/v) polyacrylamide gel (BioRad). 15 µl of
the samples were denatured by adding 5 µl 4 x loading buffer and incubation of 5 min
at 95◦C. They were spun down at room temperature and loaded into the wells of the gel
next to a low molecular weight standard. The gel was run in a tank buffer at 20 mA
for 60 min and afterwards stained with Coomassie Blue. The gel in the staining solution
containing Coomassie Blue were heated in the microwave for 30 sec and then left for 10
min on a Belly Dancer (Stoval Life Science). It was then rinsed with destilled water and
destained. The gel in the destaining solution was heated in the microwave for 30 sec and
then left on a Belly Dancer for 3 hours. Pictures were taken of each gel by a ChemiDoc
XRS+ (BioRad) using ImageLab 3.0.1 beta 2 software.
4.3 Size exclusion chromatography
The attachement between the NP+s and TH was evaluated by size exclussion chromatog-
raphy (SEC) which is also called gel filtration. At the same time, the NP-TH samples
were improved by this procedure non-boun TH which remains in solution is separated
from the TH attached to the NPs. A glass econo column (1 cm x 30 cm; Bio-Rad) was
packed with ultrogel AcA 34 (Pall Life Sciences) as described by the provider. The sepa-
ration range of the gel is 20 to 350 kDa into which a TH monomer of 56 kDa falls within.
The column was mounted in a Bio-Logic Duoflow system and calibrated with standards
to identify the elution volume of front and the end of the column.
Prior to all SEC experiments, the column was equilibrated with fast protein liquid
chromatography (FPLC) buffer (20 mM HEPES, 200 mM NaCl, pH 7.0), the UV lamp
is switched on 30 min in advance for equilibration, and the sample loop is flushed with
three times its volume, using FPLC buffer as the running buffer. The parameters used
here are a maximum pressure, limited by the ultrogel, of 7 psi and a flow rate of either
0.25 ml/min or 0.5 ml/min, depending on the sample. Fractions were collected with a
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Bio-Logic Bio-Frac Fraction Collector (Bio-Rad). This SEC procedure was only done for
NP+s, since DPPGNP+s were suspected to contaminate the column or the tubings, and
with many users of the Bio-Logic system this could not be risked.
4.4 Dynamic light scattering
To determine any change in the size of the NPs upon the presence of TH, titrations were
performed by adding increasing amounts of diluted TH to a solution of NPs. At first, the
stock TH was diluted in FPLC buffer to a concentration of 1 mg/ml. NP+ and DPPGNP+
were diluted to 0.5 mg/ml in FPLC buffer. The diluted TH stock was gradually added
to the NPs in solution and the titration samples were each time scanned in a low volume
quartz cuvette 12 µl (Hellma Analytics) in a Nanosizer S (Malvern Instruments) at 25◦C
using 173◦ backscatter angle, a refractive index of 1.330. To estimate the effect of dilution
on the DLS measurements, control samples were prepared by adding only water to the
nanoparticles.
4.5 Atomic force microscopy
The surface of the NPs was studied with AFM to observe if a structural change occured
on the surface of the NPs when TH was attached. A mica sheet (Agar scientific) surface
was cleaned by ripping off a complete layer with some Scotch Magic tape and fastened
to a microscope slide. 10 µl containing 0.05 mg/ml NP and 0.02 mg/ml TH was dripped
on the mica surface while keeping the microscope slide tilted so that the droplet spreads
over the mica surface. The sample was dried for 60-90 min under an upside down glass
beaker to prevent it from dust. The fresh sample was scanned with an ACT cantilever
(AppNano) having a tip radius of < 10 nm, a resonant frequency between 200 - 400 kHz
and a spring constant between 25 and 75 N/m. The scanning was done in an MFP-3D
AFM (Asylum research) which is mounted on an anti-vibration table (Halcyonics), using
a tapping mode, a -5% target frequency, a scan rate of 1 Hz, a set point of around 200 mV,
an integral gain of 7 and a drive amplitude of 120 mV. The images were acquired with
Igor Pro software (Wavemetrics, Inc.) and the height image was flattened while excluding
a mask covering the NPs in the modify panel. A line was drawn across the image to plot
the height profile in a 2-D graph by using the draw function in the analyse panel.
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4.6 TH activity assay
The specific activity of TH (nmol L-DOPA/min/mg) was measured by the use of 3’,5’-3H-
tyrosine according to the protocol previously described by Reinhard [44]. In this assay,
the number of radioactive water molecules produced in the catalysis equals the number of
L-DOPA molecules (Figure 4.2), which are filtered away together with unused radioactive
L-tyrosine through activated charcoal and posterior precipitation by centrifugation. The
more active TH present, the more radioactive water there will be in the sample.
Figure 4.2: Reaction in the tyrosine hydroxylase (TH) activity assay. L-tyrosine is labelled with
radioactive tritium at two positions. One of these tritiums is substituted by an hydroxyl group to give L-
3,4-dihydroxyphenylalanine (L-DOPA) and the other tritium atom ends up in a water molecule. Tritium
is displayed as a red hydrogen atom since it is an isotope of hydrogen.
The conditions in the assay were 0.1% (w/v) BSA, 100 mM HEPES buffer pH 7.0, 50
µM L-tyrosine, 20 µM Fe2+ and 0.05 mg/ml catalase. First 2 ng/µl TH was pre-incubated
in this mixture for 1 min at 37◦C, then 500 µM BH4 in 5 mM DTT was added to initiate
the reaction and incubated for 4 additional min at 37◦C. The reaction was stopped with
an excess of charcoal (7.5% (w/v) in 1N HCl).
Prior to each activity assay, TH was thawn in the cryotube, centrifuged 10 min at 4◦C
and 10000 rpm and the supernatant tranferred to a new tube. The protein concentration
of the supernatant was determined by measuring the absorbance at 280 nm measured in
the nanodrop (Saveen Werner) , based on the extinction coefficient for 1% TH = 8.14,
and using FPLC buffer as blank measurement.
The specific activity was always measured as a time scan. Each sample was incubated
at 37◦C and a small volume was taken out at 2 min, 1 h and 24 h for the assay to de-
termine the activity at that specific time. The assay itself takes only 5 min per sample
(Figure 4.3) and each condition was tested twice, with the second parallel having a 30 sec
delay in comparison to the first parallel. The results are presented as a means of the two
parallels ± standard deviation.
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Figure 4.3: Time line of the tyrosine hydroxylase assay with two parallels simultaneously
4.7 Protein labelling with fluorescent dye
3 mg TH at a concentration of 2 mg/ml was labelled at a 10% (w/w) with fluorescein
isothiocyanate (FITC). The labelling was done in a carbonate buffer of pH 9 by combining
sodium bicarbonate (NaHCO3) and sodium carbonate (Na2CO3). The basic environment
was neutralised after 4 hours by the addition of PBS. Free FITC was separated from
labelled TH by size exclusion chromatography using a Amersham Biosciences PD-10 de-
salting column. This labelling procedure was carried out in the lab of Didier Betbeder,
Univerversite de Lille 2, France. Alternatively, as done in Bergen, TH was labelled by
covalent attachment of Alexa Fluor 568 (Alexa) according to manufacturer’s instructions.
Basically, TH was labelled in a FPLC buffer supplemented with sodium bicarbonate to a
basic solution of pH 7.5 –8.5 and at a concentration of 2 mg/ml. 1 mg TH was incubated
with Alexa for 1 h at room temperature and then purified through a column containing
Bio-Rea BioGel P-30 Fine size exclusion purification resin to separate labelled protein
from free dye. The absorbance of Alexa-TH at 230 and 280 nm was measured, allowing
the calculation of the concentration (equation 4.1), where c is the concentration of the
labelled protein sample, MW the molecular weight of the protein, A the absorbance and
280 the extinction coefficient at 280 nm.
c(mg/ml) = c(M) ∗MW (g/mol) = [A280 − A230 ∗ 0.46](A.U./cm) ∗MW (g/mol)
280(cm
−1 ∗M−1) (4.1)
4.8 Cell cultures
Human bronchial epithelial 16HBE14o- (HBE) and human epithelial NCI-H292 (H292)
cell lines were grown in Dulbecco’s Modified Eagle Medium supplemented with 10% (v/v)
fetal bovine serum (FBS), 1% (w/v) glutamine (Gln), 100 U/ml penicillin and 100 µg/ml
streptomycin. Rat adrenal pheochromocytoma PC12 cell line was grown in Roswell Park
Memorial Institue medium (RPMI) supplemented with 10% (v/v) horse serum, 10% (v/v)
bovine serum, 2 mM Gln and 1 x penicilin and streptomycin mix. Human embryonic
kidney HEK293 cell line was grown in DMEM supplemented with 10% (v/v) FBS, 2 mM
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Gln and 10 U/ml antibiotic mix. Cells were grown as monolayer in T75 flasks or P100
plates (Sarstedt) with 10 ml medium at 37◦C in 5% CO2 and a humidified atmosphere.
Cell culture work with the two types of epithelial cells was performed during a two weeks
stay in the lab of Didier Betbeder, Universite´ de Lille 2 in France, whereas the work with
PC12 and HEK293 was performed in Bergen.
At confluence, the cells were splitted: The HBE and H292 cells were washed with PBS
and detached with 0.02% (w/v) trypsin for 5 min. Cells were collected by centrifugation
(5 min at 22◦C and 1500 rpm), resuspended in complete DMEM and seeded in a dilution
of 1:3. PC12 cells were mechanically detached by light tapping of the surface and subse-
quently disaggregated by repeated pipetting and forcing cells through a BD microlance
3 21G needle (0.8 x 40 mm) coupled to a 1 ml syringe. PC12 were seeded in a dilu-
tion between 1:12 to 1:2. HEK293 cells were washed with PBS, detached by treatment
of a solution containing 0.25% (w/v) trypsin and 1 mM ethylenediaminetetraacetic acid
(EDTA) (max 5 min) and seeded in a dilution between 1:12 to 1:2 in complete DMEM.
At 60–70% confluence, the cells were detached and centrifuged 5 min at 4◦C and
1250 rpm in 6 ml complete medium. The pellet was resuspended in complete medium
supplemented with 10% (v/v) dimethyl sulfoxide (DMSO) and frozen to −80◦C at a rate
of 1◦C/min. After 48 to 72 h at −80◦C, and posteriorly stored in liquid nitrogen.
4.8.1 Cellular model of protein delivery
A cell model for delivery studies was created by using cells in suspension during a splitting.
HBE and the H292 cells were seeded in 8-well Lab-Tek chamber slides in a 1:3 dilution
and the cells in the wells were grown for 24 h to develop a monolayer. PC12 and HEK293
cells were seeded at 100000 cells per well in 4-well plates (Nunc) that contained glass
coverslips previously coated with 0.01% (w/v) poly-lysine in PBS for 45 min at 37◦C.
These cells were also grown 24 h before starting experiments.
4.8.2 Sample preparation for confocal microscopy
The nuclei of the HBE cells were labelled with 0.1% (w/v) 4’,6-diamidino-2-phenylindole
(DAPI) for 5 min at room temperature (RT) and then 400 µl PBS containing 10 µg NPs
and approximately 3.5 µg TH was added and live imaging was performed immediately.
TH was incubated 10 min at room RT with each type of NPs in an approximate 1:3
(w/w) ratio before the solution was diluted in PBS. All cells except HBE, were washed
with PBS and incubated 1 h, or longer with 400 µl PBS containing approximately 3.5 µg
fluorescent TH and 10 µg NP at 37◦C in 5% CO2 and a humidified atmosphere.
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The NP-treated H292 cells were washed with 4◦C PBS and therafter fixed to the
bottom of the wells by 4% (w/v) para-formaldehyde (PFA) for 10 min at RT. Cell nuclei
were stained with DAPI for 5 min at RT and cells were washed twice with 400 µl PBS
and once with distilled water. The cells were left in water for imaging.
The NP-treated PC12 and HEK cells were washed with 400 µl 4◦C PBS and the cells
fixed to the glass coverslip by 10 min incubation with 4% (w/v) PFA at RT. The cells
were again washed twice with PBS and then once with distilled water. After removing
the water, the coverslips were mounted facedown on microscope slides using Prolong
Gold with DAPI antifade reagent (Life technologies) and left to harden overnight at RT.
Confocal imaging was subsequently performed.
4.9 Confocal microscopy
All samples were imaged with a Zeiss LSM 710 or Leica TCS SP5 laser scanning con-
focal microscope using a HCX PL Apo lamda blue objective with magnification of 63x,
numerical aperture 1.40, oil immersion and a working distance of 0.1 mm. Fluorescent
FITC-TH was excited with the 488 nm laser line from an Argon laser, whereas fluorescent
Alexa-TH was excited by a 561 nm laser line from a DPSS laser. DAPI stain was excited
using a 405 nm laser line from a laser diode. In all cases, the laser power was adjusted to
minimise photobleaching.
Zoom and field dimensions were adjusted to give a pixel size of approximately 100
nm. Single plane images were taken when most of the cell nuclei were in focus. Z-stacks
were acquired every 0.34 µm starting at the coverslip surface and ending when the cell
monolayer was out of focus. Images were processed using Fiji (freeware).
44
5 Results
5.1 Recombinant tyrosine hydroxylase (TH)
5.1.1 TH from MBP-TH fusion protein
TH was usually expressed as an MBP-TH fusion protein and the typical yield was 5 - 10
mg from 6 l bacteria cultures. TH-MBP was then cleaved by restriction protease factor
Xa at a 1:200 (w/w) ratio between factor Xa and TH-MBP. Cleaved, soluble TH was
separated from aggregates and the fusion partner MBP by size exclusion chromatography
on a HiLoad Superdex column (1.6 cm x 60 cm) as seen in figure 5.1. The fractions 9 to
15 containing the second peak were pooled as they were known to contain tetrameric TH.
The pooled fractions were upconcentrated by ultrafiltration with filters with a cut-off of
30 kDa and stored in liquid nitrogen until use.
Figure 5.1: Size exclusion chromatography as the last step in the purification of TH from MBP-TH.
The first major peak contains aggregates and the third MBP, while pure TH is in fractions 9 to 15, which
contain the second peak. These fractions were pooled and up-concentrated.
The size of both the MBP-TH fusion protein and the purified TH has been corrobo-
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rated by SDS-PAGE (Figure 5.2a). Results from size exclusion chromatography were also
analysed by SDS-PAGE (Figure 5.2b). MBP-TH cleaved by factor Xa before SEC is a
sample that consists mainly of two proteins: TH and MBP as two bands can be seen in
lane 3 of figure 5.2b.
The first peak from the bottom is the void volume of the column in which particles too
big to enter the pores of the column medium are eluted. It was represented by fraction 4
(Figure 5.1) and shows to be mainly TH (lane 4 figure 5.2b) although it is expected that
this TH is aggregated. The second peak was a pool of fractions 9 to 15 (Figure 5.1) and
corresponded to purified TH with some low molecular weight contaminants (lane 2 figure
5.2b). MBP is eluted at last and is represented by fraction 20 (Figure 5.2b lane 5) that
represents the third peak from the bottom in SEC (Figure 5.1).
Figure 5.2: SDS-PAGE analysis of the purification of TH from MBP-TH. (a) Evaluation of purification.
Lane 1: BioRad Low molecular weight standard. Lane 2: MBP-TH fusion protein. Lane 3: Purified TH
by size exclusion chromatography. (b) Effect of size exclusion chromatography. Lane 1: BioRad Low
molecular weight standard. Lane 2: TH (56 kDa) purified by SEC from fraction 9 to 15. Lane 3: Cut
TH-MBP with restriction protease factor Xa at a 1:200 ratio. Lane 4: Fraction 4 of purification after
cutting with factor Xa. Lane 5: Fraction 20 of same purification containing the MBP fusion partner (42.5
kDa).
5.1.2 TH from ZZ-TH fusion protein
Despite the high yield obtained by the procedure using MBP-TH, we appreciated cer-
tain heterogeneity in the final TH preparation and increased tendency to aggregate. We
hypothesised that this might be caused by unspecific cleavage of the fusion protein. More-
over, the yield of the expression and purification could not be increased further and restric-
tion protease factor Xa is very expensive. For these reasons, a new expression strategy
was developed. TH was to be expressed in a fusion protein with a ZZ-carrier and six
histidines at its amino terminal (a his-tag). The ZZ-carrier domain increases solubility
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and the polyhistidine-tags have an affinity for the metals nickel and cobalt, which can be
used for selection during purification by affinity chromatography.
Cloning
First, the TH gene was sucessfully amplified by PCR and inserted into the pET-ZZ-1a
vector. E. coli XL10-Gold ultracompetent cells (Statagene) were transformed with the
plasmid containing the gene for TH and colonies were screened for the presence of the TH
gene. Many colonies had sucessfully been transformed as was confirmed by electrophoresis
on a 10% agarose gel after a colony PCR as shown in figure 5.3a.
Two colonies (1A and 1B) were selected for plasmid isolation. The two plasmids were
doublechecked after isolation by electrophoresis on a 10% agarose gel as seen in figure
5.3b. It confirms the sucessful insertion as two bands appear with the first band being
the plasmid o 5724 basepairs (bp) without the gene and the second (1549 basepairs) TH
that was cut out as a test by Acc651 and Nco1. This was predictable as the TH gene is
1549 basepairs when it contains the extra ends with the restriction sites for Acc651 and
Nco1, as designed by the primers.
Figure 5.3: Agarose gel electrophoresis. (a) Initial screening for the presence of the of TH gene in the
transformed colonies. Lanes 1 and 9: 1 kb DNA ladder, lanes 2-7: colonies 1A-6A, lanes 10-15: colonies
1B-6B, lanes 8 and 16: negative controls (from transformations with water instead of ligations). (b)
Newly synthesised and isolated plasmids. Lane 1: 1kb DNA ladder. Lane 2: pET-ZZ-1a/hTH1 plasmid
isolated from colony 1A and cut with Acc561 and Nco1. Lane 3: pET-ZZ-1a/hTH1 vector plasmid
isolated from colony 1B and cut with Acc561 and Nco1.
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Expression and purification
Expression of the ZZ-TH (72.5 kDa) fusion protein was observed in the two test cultures
that were induced by IPTG (data not shown). The fusion protein was overexpressed
in E. coli strain BL21-Codon Plus(DE3)RIL (Figure 5.4a lane 2) that were grown in
autoinduction medium [43]. Soluble fusion protein was found in the crude extract after
sonication and centrifugation to remove cellular debris and insoluble proteins (Figure
5.4a, lane 3). This initial purification showed that, after metal affinity chromatography
according to manufacturer’s instructions with elution by imidazole, the fusion protein
fraction was enriched with low molecular weight contaminants (Figure 5.4a, lane 6). Also,
a lot of the fusion protein was lost in the flow-through due to saturation of the column
(Figure 5.4a, lane 5). A cutting test could however be performed on the eluated ZZ-TH.
After buffer exchange, the ZZ-TH fusion protein was cleaved at different (w/w) ratios by
Tobacco etch virus (TEV) protease. At a 1:10 (w/w) ratio between TEV and ZZ-TH,
complete cleavage was obtained at all incubation times (Figure 5.4b lane 2, 3 and 4).
Figure 5.4: SDS-PAGE of the expression and purification of TH from ZZ-TH. (a) SDS-PAGE analysis
of the presence of ZZ-TH (72.5 kDa). Lane 1: BioRad Low molecular weight standard. Lane 2: E. Coli
cell pellet. Lane 3: Crude extract of transfected E. Coli, after sonication and centrifugation. Lane 4:
Early flow through of first TALON column. Lane 5: Late flow through of first TALON column. Lane
6: Eluate of first TALON column. (b) An SDS-PAGE analysis of the cutting test and the purification.
Lane 1: BioRad Low molecular weight standard. Lane 2: TEV cleavage of ZZ-TH at 1:10 (w/w) ratio an
3.5 h incubation. Lane 3: TEV cleavage of ZZ-TH at 1:10 (w/w) ratio and 6 h incubation. Lane 4: TEV
cleavage of ZZ-TH at 1:10 (w/w) ratio and 17.5 h incubation. Lane 5: TEV cleavage of ZZ-TH at 1:100
(w/w) ratio and 17.5 h incubation. Lane 6: Early flow through of first TALON column. Lane 7: Late
flow through of first TALON column. Lane 8: TH that has been cleaved by TEV at a 1:50 TEV/ZZ-TH
ratio for 16 h. Lane 9: FLow through of second TALON column, corresponding to purified TH. Lane 10:
Eluate of second TALON column.
The bed volume of the TALON resin was then increased until 20 ml so that much less
was lost, although some loss of ZZ-TH could not be completely avoided (Figure 5.4b lanes
6 and 7). After buffer exchange to remove the imidazole, the ZZ-TH fusion protein was
completely cleaved by Tobacco etch virus (TEV) protease at an optimised ratio of 1:50
(w/w) between TEV and ZZ-TH (Figure 5.4b lane 8) and TH was purified by a second
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round on the TALON column where TH is found in the flow through (Figure 5.4b lane 9).
His-tagged ZZ fusion partner is retained in the column and eluted with imidazole before
regeneration of the resin (Figure 5.4b lane 10). The homogeneity of this preparation of
purified TH was found to be satisfactory.
5.1.3 TH labelling
To visualise the localisation of TH in cells, TH needed to be labelled with a fluorescent
dye. First, FITC was covalently attached to TH by an incubation at high pH. Successfully
labelled TH was separated from non-bound FITC by SEC using a PD-10 column (GE
Healthcare), during the purification a clear area could be observed between an orange
band containing TH and the yellow band of FITC. Fluorescence of small fractions from
the purification confirmed these results (data not shown). Later, TH was also labelled
successfully with Alexa as the purple band of labelled TH and the pink band of Alexa
were clearly separated from each other during the purification SEC. The absorbance of
Alexa-TH was measured at 230 and 280 nm and the concentration of the labeled protein
was then calculated according to equation 4.1 to be 1.73 mg/ml.
5.1.4 Enzymatic activity of recombinant TH
The enzymatic activity of TH was measured after cleavage from TH-MBP or from ZZ-TH
or after labelling giving Alexa-TH (Figure 5.5). This was to compare the two expression
methods and to see if labelling reduced the activity.
The initial activity of TH seems similar for both TH from MBP-TH, from ZZ-TH
and for Alexa-TH as the differences were found not to be significant, as seen roughly,
the variations fall within eachother’s standard deviation (SD). Typically, the activity
decreases over time. TH from MBP-TH has only half of the activity left after 1 h. TH
from ZZ-TH however seems to loose its activity much slower as very little (only around
10%) is lost after the first hour of incubation. After 24 h, the activity has decreased to
below 50 nmol L-DOPA/min/mg TH for all samples.
5.2 Binding of TH to nanoparticles (NPs)
5.2.1 Separation of free and bound TH
NP+ was incubated with TH for at least 10 min on ice and then bound and unbound
TH were separated by SEC (Figure 5.6b) using a Glass Econo-Column (diameter: 1
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Figure 5.5: Comparison of TH activity for TH expressed and purified by different methods, over time
at 37◦C.
cm; length: 20 cm) packed with Ultrogel AcA 34 media. To calibrate and to check the
homogeneity of the column, a mixture of blue dextran (2000 kDa), thyroglobulin (500
kDa) and adenosine monophosphate (AMP; 0.347 kDa) was added. Blue dextran is know
to elute in the void volume [45], which is also the front of the chromatogram (9.5 ml)
and AMP elutes in the total column volume (24 ml) (Figure 5.6a). Cytochrome c eluted
between the front and end peaks as its size (49 kDa) lies within the separation range,
while thyroglobulin is not properly separated from blue dextran.
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Figure 5.6: Size exclusion chromatography with AcaGel 34. (a) Calibration. (b) Separation.
TH gives a clear peak in the separation range, which can be seen in figure ??. The
sample with NPs and TH gives two peaks, one for the NPs loaded with TH, which are
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so big that they come in the void volume and one for the unbound TH in solution. The
second peak overlaps almost completely with the peak when TH is run alone.
The enzymatic activity was tested, to see if SEC changed TH’s activity (Figure 5.7).
When TH was run alone through the Ultrogel AcA 34 packed column as a controll, its
initial activity was at an average of 308 nmol L-DOPA/min/mg which does seem only
slightly lower than usual and could be included in the variation from day to day of initial
TH activity. The TH that is bound to NP+ seems much less active. A possible reason
is that TH is contained in the pores of NP+ so that its active site is not available for
conversion of L-tyrosine to L-DOPA. However, this activity seems to be maintained over
time.
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Figure 5.7: TH activity of TH alone (dark blue) and TH when bound to NP+ (light blue) after size
exclusion chromatography through an Ultrogel AcA 34 packed column. Incubations were performed at
37 ◦C.
5.2.2 Evaluation of NP-bound TH
To evaluate the NP-bound TH, a small sample of the fraction containing the first peak
appearing in the separation spectrum was loaded on a 10% polyacrylamide gel next to
a control of TH from SEC of the same concentration (Figure 5.8). To ensure correct
concentration measurements, the NP+s were also measured alone, but gave no signal
(data not shown) as expected, since the absorbance at 280 nm is typical for proteins.
Almost none of the NP-bound TH was denatured by SDS as can be seen by the weakness
of the band in the left lane, even though the protein amount loaded on the gel was the
same as free TH (right lane). NP+ seems to have protected TH from denaturation and
solubilisation and prevented the entering into the gel. NP+ loaded with TH seemed to
have been left in the well. This indicates that the binding was successful. The weak band
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suggests that there is an equilibrium between the bound TH and free TH and that some
can therefore be released.
Figure 5.8: Comparison of TH bound to NP+ (left lane) and free TH (right lane).
5.2.3 Size determination
To evaluate the binding between TH and the two types of NPs, a titration with increasing
amounts of TH was done and followed by DLS. The temperature during all measurements
was kept at 25◦C. To ensure that the size increase was not due to a side effect of the
inevitable dilution during the titration, a dilution control (c) was performed. All mea-
surements were done in triplicates. The results show that the average diameter of both
types of NPs increases steadily with increasing TH concentration, whereas the dilution
controls remain approximately constant (Table 5.1, figure 5.9).
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Figure 5.9: The average nanoparticle diameter versus TH concentration.
The first size increase which happens at a TH concentration of 0.01 mg/ml seems
quite small, only 5.21 nm (Table 5.1) compared to the size of TH in solution which is
approximately 12 nm (data not shown). The NPs are proposed to be porous [29] so
the enzyme could be partly included in the pores. The dilution control deviates by only
1.02 nm from the average diameter (Tables 5.1) for NP+. There can also be observed a
gap between the initial size measurements of DPPGNPs depending on if it is part of the
titration or of the dilution control. The sizes for DPPGNP and its dilution control do
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Table 5.1: Titration of NP-samples with increasing amounts of TH, followed by DLS
Sample [TH] (mg/ml) Z-ave (nm) ± (nm) PdI
NP-1 0.00 52.33 0.2970 0.167
NP-2 0.01 57.54 0.4405 0.25
NP-3 0.025 64.42 0.4518 0.268
NP-4 0.05 79.73 7.031 0.403
NP-5 0.10 105.9 5.173 0.525
NP-1 c - 53.35 0.4172 0.186
NP-2 c - 53.05 0.5405 0.180
NP-3 c - 52.65 0.2139 0.182
NP-4 c - 53.50 0.8884 0.185
NP-5 c - 53.86 1.496 0.206
DPPGNP-1 0.00 188.1 2.836 0.282
DPPGNP-2 0.01 197.5 4.289 0.268
DPPGNP-3 0.025 205.7 3.528 0.274
DPPGNP-4 0.05 210.8 0.9504 0.284
DPPGNP-5 0.10 220.9 1.762 0.266
DPPGNP-1 c - 156.6 3.190 0.260
DPPGNP-2 c - 160.9 2.955 0.284
DPPGNP-3 c - 163.4 3.424 0.276
DPPGNP-4 c - 166.8 2.281 0.272
DPPGNP-5 c - 168.3 1.308 0.263
not correspond at the beginning of the measurement. One plausible reason could be the
effect of the ions in the buffer solution which affect the ordering of the lipids.
5.2.4 Visualisation of the nanoparticles containing TH
To observe any structural change to the surface of the NPs upon TH attachement, the
NPs were scanned by AFM. 10 µl droplets of NP samples were spread on mica which was
fastened to a microscope slide. The NP concentration was optimised to 0.05 mg/ml as
that gave a monolayer of particles with such spacing between them that was suitable for
imaging. When TH was present in the sample, its final concentration was 0.02 mg/ml.
Dilutions were done i water as buffer and salt increased crystal formation and high back-
ground in the AFM images. Crystals could still be observed in many samples and the
areas that were scanned were selected such that they did not contain crystals, but rather
have a suitable spacing between NPs.
The imaging was done after drying the sample drop on the mica for 60-90 min. All
samples were imaged three times at three different spots on the slide to ensure that the
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pictures are representative. An overview image of either 20 µm × 20 µm or 5 µm × 5 µm
was always scanned first before a 1 µm × 1 µm zoom was made. The best images were
selected and their height profiles analysed.
NP+ is seen as a red spot in the height image with a yellow background (Figure 5.10a)
meaning that it is higher than the rest of the sample surface. And when its dimensions
are analysed from height profiles like the one in figure 5.11, the diameter is 190 nm and
the height is 5 nm. NP+ can also be seen in both the amplitude (Figure 5.10b) and the
phase (Figure 5.10c) images. The background seems to have a pattern reminding of a
knitted jumper. This is the structure of the mica surface because it is exactly what is
seen when only the mica surface is imaged (data not shown).
Figure 5.10: NP+ imaged by AFM in (a) height, (b) amplitude and (c) phase mode.
Figure 5.11: Height profile of NP+
DPPGNP+ gave similar results to NP+ (Figure 5.12) although these lipid containing
NPs look a bit like fried eggs with a thin bottom level and a thicker core. This is especially
visible in the amplitude mode (Figure 5.12b) The height profiles (like figure 5.13) give
larger dimensions than for NP+ which is as expected. The bottow level has a diameter
of almost 400 nm and a height of 4 nm and a top level of 200 nm in diameter and 6 nm
high.
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Figure 5.12: DPPGNP+ imaged by AFM in (a) height, (b) amplitude and (c) phase mode.
Figure 5.13: Height profile of DPPGNP+
When NP+ are loaded with TH, the background in the images appeared to have
changed independent of the visualisation mode (Figure 5.14). The NP+ are still compa-
rable in size although the height is now 8 nm (Figure 5.15) instead of 5 nm. It is difficult
to say if this change is due to the presence of TH or not. The diameter even seems a little
smaller: 170 nm instead of 190 nm. TH could give the porous NP+ more rigidity so that
the AFM scan comes closer to the real dimensions. The phase image (Figure 5.14c) shows
a dark area where the NP+ loaded with TH is located. TH seems therefore to change the
phase in the opposite direction than what NP+ itself does.
The background is crowded when DPPGNP+s loaded with TH are imaged (Figure
5.16). It is difficult to know if this represents aggregated NPs or only TH which also
might be aggregated to give larger structures than its own size. Some blue spots can be
observed in the phase image. The DPPGNP+ loaded with TH seems 12 nm in height and
350 nm in diameter according to one of the height profiles (Figure 5.17).
NP+s loaded with TH after separation from unbound TH by SEC provide a much
flatter background (Figure 5.18) than when the sample of TH bound to NP+ was not gel
filtrated to take away unbound TH (Figure 5.14). This is better appreciated in the heigth
profile (Figure fig:NP+THSECS). However gel filtration also seems to have taken away
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Figure 5.14: NP+ with TH imaged by AFM in (a) height, (b) amplitude and (c) phase mode.
Figure 5.15: Height profile of NP+ with TH.
some of the loaded TH as the phase image (Figure 5.18c) shows less dark areas on the
particle itself. This can explain the huge decrease in activity when TH is bound to NP+
and all unbound TH is removed by SEC.
The maximum height that can be read from the profile is 30 nm for this sample and
this seems more reasonable than the value obtained previous to filtration, which was 12
Figure 5.16: DPPGNP+ with TH imaged by AFM in (a) height, (b) amplitude and (c) phase mode.
56
5.2 Binding of TH to nanoparticles (NPs)
Figure 5.17: DPPGNP+ with TH height profile
Figure 5.18: NP+ loaded with TH imaged by AFM after SEC in (a) height, (b) amplitude and (c)
phase mode.
nm (Figure 5.15), as it is more in accordance to the actual height. Thus, it seems that gel
filtration is successful in removing some background from free TH that deposits on the
mica, though another explanation could be that this image was taken at a later stage of
my thesis, so that I had more experience with the settings adjustments.
For all samples, a deformation of the NPs could be observed. The NPs’ sizes are
expected to be 65 and 90 nm for NP+ and DPPGNP+, respectively, [Didier Betbeder,
Figure 5.19: NP+ with TH after SEC height profile
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personal communication] and observed to be quite spherical by electron microscopy [29],
but the NPs seemed always larger and thinner when imaged by AFM. The sample prepara-
tion includes drying which might force the NPs to collaps since they are porous. Another
reason could be the type of tip used. The tip material might not be suitable for such soft
biological samples.
5.3 TH stabilisation
As already seen in figures 5.5 and 5.7, TH activity decreases over time, and in order to
test if this inactivation could be reduced we investigated the effect of several additives for
TH samples both when free in solution and when bound to NPs. Gel filtration was not
performed in these experiments. The initial activity of the enzyme varies from day to day
due to experimental variations as exact concentration, amount of radioactively labelled
L-tyrosine present in mix and the time delay between TH was thawn, but left on ice and
the start of the experiment. We therefore tried to be as consequent with the conditions
and accurate as possible in all experiments.
The effect of the NPs on TH activity and stability was first checked by compar-
ing the two types of NPs to an inorganic NP made of gold and functionalised by 11-
mercaptoundecanoic acid (MUA) [46], as can be seen in figure 5.20a. The NPs seem to
have an intrinsic stabilising effect with NP+ surpassing the activity level of TH alone
after 1 h, whereas DPPGNP+ has higher activity than TH alone only after 24 h. When
data from five independent experiments are pooled, the same trends are visible and it is
possible to statistically analyse the significance of the differences (Figure 5.20b). Each
experiment, which always has two parallels per sample, tested at least two of the three
samples displayed. The means were therefore calculated from six to ten parallels.
According to the report from a Holm-Sidak test (Appendix A.1) generated by SigmaPlot
12.0.0: ’The difference in the mean values among the different...sample[s] is greater than
would be expected by chance after allowing for effects of differences in time. There is a
statistically significant difference (P = 0.037).’ However, when comparing the samples
within one time group, the only significant difference (P < 0.05) was found to be at 2
min when TH-DPPGNP+ was compared to TH alone or to TH-NP+, with P = 0.007 and
P = 0.035, respectively. This means that the initial decrease in activity upon binding to
DPPGNP+ is significant, whereas the long term stabilising effect by NP+ or DPPGNP+
are not. When NP+ and DPPGNP+ are compared to TH alone within the 24 h group,
P = 0.414 and P = 0.712, respectively.
To increase the long-term activity of TH at 37◦C even further, several stabilisers were
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Figure 5.20: The effect of different NPs on TH activity over time and at 37◦C. (a) in comparison with
Au-MUA or (b) when combining five independent experiments.
tested (data not shown). Among them, BH4 and compound III (3-amino-2-benzyl-7-
nitro-4-(2-quinolyl)-1,2- dihydroisoquinolin-1-one) [47] did not increase TH activity at
any time. The combination of catalase and superoxide dismutase (SOD) was however
positive. Catalase and SOD are enzymes responsible for the oxidation state of the internal
environment of the cell. TH requires a Fe2+ metal ion in its active site to be able to
hydroxylase tyrosine. Since Fe2+ is easily oxidised to Fe3+, it is important to protect
Fe2+. Both dopamine and compound IV also showed a stabilising effect on TH activity
after 24 h. The stabilisers with the best effect on the long run were also tested in the
presence of the two types of NPs (Figure 5.21).
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Figure 5.21: The effect of stabilisers on TH activity when (a) NP+ or (b) DPPGNP+ is present.
For NP+ the highest activity after 24 h was obtained when Cat and SOD were present
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(Figure 5.21a). When TH was bound to DPPGNP+, dopamine seems the best stabiliser
(Figure 5.21b).
5.4 Cell uptake of TH bound to NPs
Uptake of NP-bound TH was evaluated in four different cell types that were derived from
human epithelium, rat pheochromocytoma or human embryonic kidney. The two types of
epithelial cell lines, human bronchial epithelial (HBE) and human epithelial H292, were
customarily used in the lab of Prof. Didier Betbeder to study the uptake of NPs bound
to drugs or proteins for therapeutic delivery through the respiratory tract. Therefore we
chose to use them as our model to investigate the uptake of NP-bound TH into cells.
PC12 cell line is derived from rat pheochromocytoma, which is a mild tumour of
the adrenal medulla, a neuroendochrine tissue. It is a well-established cellular model
for neuronal research and was selected due to its relevance to ERT for PD and related
malignancies. Addition of neuronal growth factor to PC12’s cell culture induces the
formation of neurites, characteristic protrusions of neurons [48]. Neurites is a general
term which can mean both dendrites and axons. PC12 cells intrinsically express high
levels of TH, so the internal cellular environment is adapted to TH.
Human embryonic kidney cells (HEK293) were selected to serve as a model that did
not contain any intrinsic TH. An up-take study was necessary for the possibility of a
future evaluation of TH’s functionality, to see if TH is still enzymatically active after
delivery.
5.4.1 Initial testing with human epithelial cells
For cell culture experiments, purified TH protein labelled with FITC, which has a maxi-
mum emission at a wavelength of 521 nm, was used. HBE cells grown on 8-well Lab-Tek
chamber slides (Thermo Scientific) were incubated for 30 min with either FITC-TH or
FITC-TH bound to either NP+ or DPPGNP+. The cell nuclei were stained by 5 min
incubation with DAPI, a dye with high affinity for the nucleus. Live imaging was per-
formed using a Zeiss LSM 710 confocal microscope and 63x objective with oil immersion
(Figure 5.22).
Only a few green spots, corresponding to FITC-TH, could be observed when TH alone
was incubated with HBE cells (Figure 5.22a). It is possible that this TH corresponds to
protein slightly associated with the outer cell membrane. When NP+ are used for TH
delivery to HBE cells (Figure 5.22b) much more TH can be seen in the cells. Large
green spots indicate that TH is aggregated there, but also faint green shadows can be
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Figure 5.22: Distribution of FITC-TH (green) in living HBE cells visualised with confocal microscopy.
Cell nuclei were stained with DAPI (blue). Scale bar is 10 µm. (a) TH alone, (b) TH bound to NP+ and
(c) TH bound to DPPGNP+.
seen to line up which might indicate that TH bound to NP+ is associated to the plasma
membrane. When TH is delivered by DPPGNP+ aggregates seem still to appear, but
faint green shadows encircle the bluish labelled nuclei (Figure 5.22c). This indicates that
TH is present in the cytosol.
The other human epithelial cell line, H292, grown on 8-well Lab-Tek chamber slides
(Thermo Scientific), was incubated 1 h with either FITC-TH, or FITC-TH bound to
either NP+ or DPPGNP+ at 37◦C. The cells were fixed and then washed so that TH,
that was not taken up by the cells, would be removed. Images from H292 were then taken
with a Zeiss LSM 710 confocal microscope (Figure 5.23). For the H292 cells, TH seen as
bright green spots, possibly from TH aggregates, dominate the images for all conditions.
Only when TH is delivered by DPPGNP+, some homogeneously distributed TH can be
observed (Figure 5.23c).
Figure 5.23: H292 cells treated with (a) FITC-TH (green) alone, (b) TH with NP+ and (c) TH with
DPPGNP+. Cell nuclei are labelled with DAPI (blue). Scale bar is 10 µm.
Both human epithelial cell types seem not to have formed perfect monolayers as not
all nuclei are in focus in the images. Confocal microscopes have very narrow focal planes,
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so that there is a slight difference in the plane position of sample features, these rapidly
goes out of focus in the image. An explanation for the absence of focus of some nuclei
in the images is that nuclei are in different planes in each cell, whereas annother less
plausible is that the cells have grown to form multiple layers.
5.4.2 Colocalisation of NPs and TH within epithelial cells
DPPGNP+ that had been labelled with dioctadecyl tetramethylindocarbocyanine per-
chlorate (DiI) were used for an evaluation of the DPPGNP+ position compared to TH,
and to see if TH would be released after cell uptake. DiI has a maximum emission at
a wavelength of 565 nm. Colocalisation of TH and DPPGNP+ is shown in yellow as
the superposition of red and green. HBE grown on 8-well Lab-Tek chamber slides, were
imaged live after 30 min incubation with FITC-TH and DiI-DPPGNP+ at 37◦C and 5
min staining of the cell nuclei with DAPI (Figure 5.24).
Figure 5.24: Colocalisation of FITC-TH (green) and DiI-DPPGNP+ (red) in HBE cells imaged live.
The colocalisation can be seen as yellow which is the superposition of red and green. Scale bar is 10 µm.
(a) Green signal from FITC-TH, (b) red signal from DiI-DPPGNP+ and (c) the merged image of red
and green showing the colocalisation, and where the blue signal from the DAPI-stained cell nuclei can
also be observed.
TH seems to bind to DiI-DPPGNP+ given that the merged image from the green
and red channels renders some bright yellow signals that are interpreted as colocalisation
(Figure 5.24c). Nevertheless, not all NPs bind TH, given that in the merge image some
red signals can be detected. Moreover, some of these are very bright probably indicating
aggregated DiI-DPPGNP+. Neither is all FITC-TH bound by NPs as some bright green
spots can be seen in the same image. These bright green spots probably correspond to
aggregated TH that is located outside the cells, which means that aggregated TH is not
bound to DPPGNP+ nor taken up into the cells. For the homogeneously distributed TH
and NPs, it is more difficult to conclude if they colocalise or not and if TH is delivered
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to the cell and then released.
Slightly different results were obtained when using the H292 cellular model (Figure
5.25). H292 cells grown on 8-well Lab-Tek chamber slides (Thermo Scientific), were
incubated with FITC-TH and DiI-DPPGNP+ for 1 h at 37◦C. The cells were washed,
fixed and stained with DAPI for 5 min and then imaged.
Figure 5.25: Colocalisation of FITC-TH and DiI-DPPGNP+ in fixed H292 cells. Scale bar is 10 µm.
(a) Green signal from FITC-TH, (b) red signal from DiD-DPPGNP+ and (c) the merged image of red
and green showing the colocalisation, and where the blue signal from DAPI-stained cell nuclei can also
be observed.
The merged image from the FITC-TH and the DiI-DPPGNP+ channels renders mainly
a yellow signal (Figure 5.25c) indicating that TH binds to NP+. NP+ do not seem to
aggregate given that no bright red spots can be observed in the merged image although
some aggregated TH that is not bound the NP+ is still observed as bright green spots in
the merged image.
5.4.3 TH uptake into PC12 cells
For experiments to evaluate the uptake of TH to PC12 cells, TH labelled with Alexa Fluor
568, which has a maximum emission at a wavelength of 603 nm, was incubated with NP+
or DPPGNP+ for 10 min. Afterwards the PC12 cells, grown on coverslips coated with
poly-lysine, were incubated with these mixtures or Alexa-TH alone for 1 h at 37◦C. Cells
were fixed and mounted using a reagent with DAPI that labels the cell nuclei. Cells were
imaged with Leica TCS SP5 and images for the emission of fluorescence from Alexa and
DAPI as well as bright field images were acquired. Control samples consisting of PC12
cells left untreated, showed no autofluorescence in the emission spectrum range detected
(images not shown). The results of the treated PC12 cells show the same trends as for
the epithelial cells. Both NPs increase the presence of Alexa-TH in the cytosol (Figure
5.26).
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Figure 5.26: Distribution of Alexa-TH (red) in PC12 cells incubated with (a) TH alone, (b) TH with
NP+ (c) TH with DPPGNP+. Cell nuclei are labelled with DAPI (blue). Scale bar is 10 µm.
It was also possible to observe PC12 cells that spontaneously had developed protru-
sions similar to dendrites and axons of neurons (Figure 5.27).
Figure 5.27: PC12 cell with neuronal morphology that has been incubated with Alexa-TH (red) bound
to DPPGNP+. Cell nuclei are labelled with DAPI (blue). Scale bar is 10 µm. (a) Blue signal from DAPI
stained cell nucleus. (b) Red signal from Alexa-TH. (c) Superposition of blue and red signal. (d) Bright
field image of PC12 cell with neuronal morphology. (e) Superposition of all signals.
Some background signal from Alexa-TH can be observed when TH is delivered by
either NP+ (Figure 5.26b) or DPPGNP+ (Figure 5.26c). A possible reason for this is that
the cells were seeded on poly-L-lysine coated glass coverslips to which labelled protein
or the NPs might attach. We did not succeed in reducing the background even when
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extensive washing with warm PBS was performed, instead of one wash with PBS at
4◦C. Incubation time lapses of 1 to 3 h were carried out in order to identify the optimal
incubation time for PC12 cell cultures. Nevertheless, the results did not show differences
among the different incubation times (data not shown) and therefore 1 h incubation was
chosen for further experiments.
5.4.4 TH uptake into HEK293 cells
HEK cells grown on coverslips coated with poly-lysine, were incubated with either Alexa-
TH or Alexa-TH bound to NP+ or DPPGNP+, for 1 h at 37◦C. Alexa-TH was bound
to each NP by 10 min incubation at RT. HEK293 cells were fixed, counter stained and
imaged using Leica TCS SP5. Images for the emission of fluorescence from Alexa and
DAPI were acquired as well as bright field images. Proper controls were also carried out
with HEK293 cells that were left untreated, and no signal was detected, as expected (data
not shown). The images of the NP treatment of HEK293 cells show similar results as for
the other cell types (Figure 5.28). A clear difference between TH uptake when TH was
not delivered by any NP (Figure 5.28a) compared to when it was delivered by either NP+
(Figure 5.28b) or DPPGNP+ (Figure 5.28c) was observed. TH when delivered by any
type of NP seems to cluster together in HEK293 cells, as is seen by the bright red spots.
Figure 5.28: Distribution of Alexa-TH in HEK293 cells. Cell nuclei are labelled with DAPI (blue).
Scale bar is 10 µm. (a) TH alone, (b) NP+ with TH and (c) DPPGNP+ with TH.
5.4.5 Penetration of TH in Z-direction
Despite the fact that all the cellular experiments and imaging described so far, indicated
that TH was taken up by the cells, it is important to consider the possibility of imaging
artefacts. In all cell types TH seems to be associated with the cells in some way or
another when either NP+ or DPPGNP+ was present. It seems that TH must have crossed
65
Results
the plasma membrane, but TH could just as well be associated to the outside of the
plasma membrane or located within. To determine the exact location, z-stacks have been
performed on all cell types and for both types of NPs. A z-stack is a series of images where
the focus for each image is slightly moved in the Z-direction compared to the previous
image and thus imaging many slices of the cell.
When TH delivery by DPPGNP+s to H292 cells was imaged with the focus above
most of the cell nuclei, FITC-TH appears mostly as aggregates, whereas some homoge-
neously distributed FITC-TH can also be observed in green (Figure 5.29a). Much more
homogeneously distributed TH can be observed when the focus penetrates deeper into
the cells (Figure 5.29b), whereas less TH penetrates all the way to the bottom the cells
(Figure 5.29c).
Figure 5.29: Localisation of FITC-TH delivered to H292 cells by DPPGNP+ at different planes. (a)
On the surface, (b) in the middle and (c) at the bottom
Slices of a PC12 cell that has developed neuronal morphology were also taken (Figure
5.30). When the focus is in the top part of the cell, some Alexa-TH can be observed where
the cell is thickest (Figure 5.30a). The slice containing the middle of the nucleus shows
much more TH present in the cytosol (Figure 5.30b). The bottom of the cell, much TH
can be observed in the protrusions that extend along the glass coverslip (Figure 5.30c).
A side view of all the z-stacks was generated by the imaging software Imaris (Bitplane)
and shows the presence of TH (Figure 5.30d).
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5.4 Cell uptake of TH bound to NPs
Figure 5.30: Localisation of Alexa-TH at different planes in PC12 when delivered by DPPGNP+. (a)
On the surface, (b) in the middle, (c) at the bottom and (d) side view of the cell.
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6 Discussion
It has long been difficult to treat diseases of the brain because it is such a well protected
organ. NPs as drug delivery tools have earlier been shown to be effective for the delivery
of small drug and the improvement of treatments addressing brain diseases like epilepsy
[49], Alzheimer’s disease [50] and brain tumours [51]. The general purpose of this master’s
thesis has been to investigate the binding of TH to NPs and their uptake into different
cell types, as a very preliminary step in the evaluation of a ERT for the treatment of
dopamine deficiencies and notably PD and related malignancies. In this context, TH is
the enzyme of interest because L-DOPA therapy is the standard treatment for PD. It is
expected that TH delivered in situ would be able to increase the amount of L-DOPA in
the brain when L-tyrosine, BH4 and Fe
2+ are naturally present. The NPs studied here
have been selected according to their properties: NP+ and for its ability of crossing the
BBB [34] and DPPGNP+ for its ability to avoid opsonisation [29] and for better protein
delivery to cells [Didier Betbeder, personal communication].
6.1 Tyrosine hydroxylase (TH)
At the start of the project, TH was recombinantly expressed in E. coli as a fusion protein
with MBP. A new strategy using ZZ as the fusion partner instead of MBP, was developed
to improve the quality of purified TH. TH purified from the latter method, showed a higher
activity after 1 h of incubation at 37◦C (Figure 5.5) and a lower tendency to aggregate.
Thus, the ZZ-fusion strategy appears beneficial. Optimisation by testing different E. coli
strains and varying the induction temperature is expected to further lead to increased
yield of the new expression method.
TH activity has previously been shown to be unstable, and the loss of activity over
time, which has measured as a 22% loss of the initial activity after 10 min at 37◦C and
pH 7.0, has been explained to be caused by an inactivation rather than a denaturation
of the protein [52]. The decrease in activity measured in this work, was 57% after 1 h of
incubation at 37◦C (Figure 5.20b). Assuming an exponential decrease of the TH activity,
the predicted decrease after 10 min would be 12% which is comparable to that reported.
Part of the measured decrease of TH activity is caused by denaturation and aggrega-
tion [25]. Aggregation is a phenomenon to which all proteins are prone to in a certain
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extend. Protein aggregates are toxic for human. There exist diseases like Alzheimer’s and
Huntington’s disease where protein aggregates are the triggering factors [53]. The propen-
sity of TH to aggregate, thought observed in vitro, has been associated to putative toxic
states in vivo [25, 52]. Aggregates are especially observed when the TH batch is frequently
frozen and thawn or after a dilution (data not shown). In addition, TH is not a simple
protein, but a large enzyme consisting of four subunits and an easily oxidised Fe2+ at its
catalytic site. PAH aggregation has been shown to be much more frequently happening
in the iron free apo-PAH than in the holo-enzyme [24]. Temperature jumps or dilution
jumps could easily induce small conformational changes which change the catalytic site
and result in loss of activity. The aggregation propensity is not solely characteristic of the
recombinant enzyme. In fact, when TH was purified from bovine sources, the aggregation
was so severe that the standard procedure was to solubilise TH by proteolytic digestion
with trypsin [54]. This gave a truncated form of TH of only 34 kDa compared to the 56
kDa per subunit of recombinant TH.
TH activity measurements indicate that there is a trend showing that both NP+ and
DPPGNP+ stabilise TH, whereas the gold NPs coated with MUA show little stabilisation
effects (Figure 5.20). Synthetic polymers have earlier shown to stabilise proteins by hy-
drophobic interactions [55]. Sugars have also been used to protect proteins from storage
induced stress when proteins are integrated in NPs [56]. The use of polymeric NPs made
of mainly maltodextrin might therefore aid to the conservation of TH for therapeutic use
in addition to facilitate in the enzyme delivery (see below).
The enzymes that are responsible for the redox balanced environment in the cytosol,
catalase and SOD, gave an additional stabilisation effect to the TH that was bound to
either NP+ or DPPGNP+ (Figure 5.21). The correct oxidation state of the iron atom
at the catalytically active site of TH is necessary for TH to be active. Martinez et al.
showed that when the iron free apo-enzyme TH was reconsituted with Fe2+ an increase in
stability, but no conformational change could be observed [57]. By ensuring the correct
oxidation state of iron, increased stability is obtained. This might be due to prevention
of Fenton’s reactions induced by iron that might lead to changes around the active site
and aggregation, as explained above.
In vivo, TH activity is tightly regulated by both phosphorylation and end product
inhibition [22]. Phosporylation increases TH activity. A synergy between catecholamine
binding to the active site and phosphorylation is also proposed as the serine 40 phospho-
rylation decreases the affinity for catecholamine binding [58]. TH activity is regulated by
the cytosolic concentration of dopamine and other catecholamines through feed-back in-
hibition. The initial inhibition observed by dopamine addition to TH bound to both NP+
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and DPPGNP+ (Figure 5.21) was therefore expected. Since dopamine would dissociate
when the cytosolic level drops, dopamine could also stabilise TH in the long run, which
was also observed for both NPs.
6.2 Nanoparticles (NPs)
The size of both types of NPs are reported to be around 60 nm in z-average diameter [29].
The sizes of the NPs batches used, are 66 nm and 85 nm for NP+ and DPPGNP+, respec-
tively [Didier Betbeder, personal communication]. However, when measuring the sizes by
DLS, we only reproduced the expected size for NP+, whereas the size of DPPGNP+ was
150 to 250 nm (Figure 5.9). The size of NP+ was measured to be 53 nm in diameter
which is a little smaller than reported. The reason for this difference is most probably
the salt content in the buffer used. FPLC has 200 mM NaCl which is comparable to
physiological salt levels, while the reported size was measured in 15 mM NaCl [29]. Since
NP+ is a charged particle, the water molecules will orient in such a way to cancel out
the charge. The water close the the particle surface therefore forms a layer with rigid
structure. DLS measures the hydrodynamic diameter which can not distinguish between
the particle itself and the water shell around. The difference in the size of NP+ is likely
to be due to a difference in the thickness of the water shell. The more salt a solution
contains, the faster it can cancel out a charge by including many counter ions in the shell
of oriented water molecules.
AFM is a powerful tool with high resolution, but it is difficult to use for biological
samples. When imaging metallic NPs, however, the size can easily be determined by AFM
as the difference between background and particle is big as can be seen in the images of
the silver NPs taken by Al-Sid-Cheikh et al. [59]. In all images that have been taken
for this project, it has been observed that the organic NPs are deformed to a greater or
lesser extend. A possible explanation is that sample preparation, which includes drying
of the NPs, leads to deformation. Since the NPs are porous, it is likely that they collapse
into a pancake seeming flatter and appear lower than they are in solution. AFM images
of other NPs do also show a lower height than the diameter given by DLS [60, 61]. To
bypass this deformation, it would be required to image in liquid with AFM, although this
requires some extra expertise with the set up.
The images of NP+ after free TH had been separated from bound TH gave a height of
30 nm which approaches the DLS results. Here the diameter in the AFM pictures was at
least the same as given by the DLS. It has been difficult to observe any structural change to
the surface and it might be that cryo-electron microscopy (cryo-EM) can help visualising
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the NPs better. The NPs are then frozen down so quickly that they are expected to keep
their structure. This is typically done as part of NP characterisation in addition to AFM
and DLS [61].
The phase image of the AFM is not as extensively used as the height image. The
structure of rubber blends has however been investigated, since the topography was not
depended on the structure [62]. The phase image gives information on the interactions
between the tip and the surface instead of the topography. In our study of NPs with
TH there can be seen quite a change in the phase retrace images when TH is added to
the NPs. The phase shift is negative (blue in figure 5.14) when TH is present instead of
positive (red in figure 5.10) when TH is absent. It is likely that this change of phase is a
’signal’ from TH. However, care has to be taken in these interpretations, since the phase
depends on the voltage applied to the cantilever.
6.3 TH-NP conjugate
NP+ do not absorb UV light at 280 nm as is typical for proteins where this absorption
arises from the presence of aromatic residues. This presents a difficulty for concentration
measurements, but it is an advantage when performing SEC experiments, where the first
peak in the sample with NPs and TH should therefore come from TH bound to NP+s
since the NP+ do not give any UV signal (Figure 5.6b).
Development of ERT of mitochondrial neurogastrointestinal encephalomyopathy has
been improved by incorporating the enzyme of interest, thymidine phosphorylase, into
polymeric NPs [63]. No inflammatory responses were observed in vivo and enzyme activity
decreased only a little during incubation in blood. It seems therefore plausible that further
investigations into the NP-TH-conjugate could lead to a development of ERT of PD or
TH deficiencies.
6.4 Uptake studies
Confocal images taken during this project, show the presence of TH (green or red depend-
ing on the labelling) in the plane of the cell nuclei of all types after 1 h of incubation with
TH bound to the NPs. Evidence of NP+ uptake in HBE cells after 3 min of incubation
is reported and the fluorescence from labelled NP+ appears to reach a plateau in these
cells after 30 min [31]. The uptake might however be cell type dependent as the human
epithelium is designed to attach and internalise foreign particles. The HEK293 cells did
not seem to take up TH to the same extend as the PC12 or the epithelial cells. Elongated
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incubation did not increase the uptake, and shorter incubation should therefore be tested.
It could be that HEK293 cells take up NPs faster but also degrade or excrete them faster.
This is theoretical contradictory since PC12 are cells used to secrete hormones all the
time and HEK293 cells are not.
In many of the samples, big aggregates of intensely fluorescent TH at high saturation
can be observed. Many of these aggregates seem to be at the cell surface as they appear
in the planes where the nuclei are not at their brightest fluorescence. Since aggregates
are not the TH we are interested in, and since this TH has probably not penetrated the
cell membrane, the fluorescence of the aggregates can be considered an artifact. The
experiment must therefore be improved to eliminate or at least diminish the formation
and presence of aggregates. This can be done by a more extensive washing procedure prior
to imaging. There exist numerous detergents that could improve the washing procedure
and solve aggregates that have associated with the cell membrane. Some detergents like
BSA, Tween or Triton could be tested and compared.
To distinguish the exact location of TH as outside but bound to the plasma mem-
brane or in the cytosol, further experiments with plasma membrane markers have to
be performed. Fluorescently labelled lipid NPs have been observed as both bound and
internalised into HEK293(β3) cells using confocal microscopy and flow cytometry [64].
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7 Concluding Remarks
Results from using the different methods applied in this thesis imply that TH binds
to both NP+ and DPPGNP+. There is a size increase observed in the DLS, a change
in the AFM phase image and an additional peak in the UV spectrum of SEC. It can
therefore be proposed that TH is absorbed into the porous NPs investigated, although
the specific interaction between the enzyme and the particle, a priori expected to involve
the regulatory N-terminal, has not however been determined by more specific methods.
A tendency of increased TH activity after 24 h was seen when TH was incubated in the
presence of either NP indicating a stabilisation effect from the NPs. Catalase and SOD
or dopamine could also increase this stabilisation effect further for NP+ and DPPGNP+,
respectively.
The images from the confocal microscopy analysis suggest that both NPs can deliver
TH to different types of cells, whereas TH itself is not taken up by the cells.
This project has been very exciting to work with and has revealed the potential of
the approach investigated to develop into a therapeutical application. In addition it has
allowed to get acquainted with a number of state of the art methods, spanning from
biochemistry and biophysics to cellular biology.
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8 Future perspectives
An optimization of the NP to TH ratio would be an important focus for future work,
since the NPs need to be positively charged in order not be opsonisated by proteins of
the immune system in the blood [29]. In addition, this optimization can give information
about the concentration of TH that provides maximal saturation. One approach to obtain
proper titrations is to study if there is a change in the surface charge of the NPs upon
binding of TH through measurements of zeta potential similar to the titration as was done
for the size evaluation of the NPs as reported [65].
One of the next steps in the cell culture experiments would be to use a cell model for
the BBB which can be bought commercially. This model is a kit consisting of two cell
cultures: one endothelial cell line and one neuronal cell line. These cell types are grown
each on its own side of a filter or membrane and serve as an artificial BBB. TH penetration
across the filter from the endothelial towards the neuronal side can then be measured by
concentration measurements and give an idea of the extend of BBB transcytosis.
It is not only important that TH enters physically into the brain, but also that it
retains its functionality. This can be investigated by measuring TH activity of cell lysates
before and after NP treatment. It has therefore been important to switch from PC12 cells
to another cell line that does not have any intrinsic TH. The presence of intrinsic TH is
also a disadvantage as it makes it difficult to measure the TH activity of the delivered
TH as the background from the intrinsic PC12 TH will be so high. Therefore HEK293
cells were selected to serve as a model to evaluate in the near future if TH’s functionality
is conserved. A challenge of this planned experiment is however that if TH is not taken
up into the cytosol of the cells, it might still be present in the lysate if it was associated
to the plasma membrane in one or another way. Removal of TH bound to the outside of
the plasma membrane has to be ensured before the measurements are performed.
At last but not at least, it is of great importance that some toxicology studies are per-
formed on the NPs with TH. If an ERT is one day ready for patient trials, the nanocarriers
should not be toxic or give any undesired effects. The study that could be performed at
this moment are cell growth measurements in a controlled cell counter device which gives
an indication if the NPs with TH might induce unwanted effects or even cell death.
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A Appendix
A.1 Holm-Sidak test
Two Way Analysis of Variance lørdag, februar 18, 2012, 14:29:26
Data source: Rel from 5 exp ANOVA in 20120208 Comparison TH w NPs version 12
General Linear Model
Dependent Variable: Activity
Normality Test (Shapiro-Wilk) Passed (P = 0,292)
Equal Variance Test: Passed (P = 0,656)
Source of Variation  DF  SS  MS   F   P 
Sample 2 4685,206 2342,603 3,452 0,037
Time 2 45734,857 22867,429 33,692 <0,001
Sample x Time 4 5565,567 1391,392 2,050 0,097
Residual 67 45473,877 678,715
Total 75 106478,971 1419,720
The difference in the mean values among the different levels of Sample is greater than would be expected
by chance after allowing for effects of differences in Time.  There is a statistically significant difference (P
= 0,037).  To isolate which group(s) differ from the others use a multiple comparison procedure.
The difference in the mean values among the different levels of Time is greater than would be expected by
chance after allowing for effects of differences in Sample.  There is a statistically significant difference (P =
<0,001).  To isolate which group(s) differ from the others use a multiple comparison procedure.
The effect of different levels of Sample does not depend on what level of Time is present.  There is not a
statistically significant interaction between Sample and Time.  (P = 0,097)
Power of performed test with alpha = 0,0500:  for Sample : 0,467
Power of performed test with alpha = 0,0500:  for Time : 1,000
Power of performed test with alpha = 0,0500:  for Sample x Time : 0,306
Least square means for Sample :
Group Mean SEM
TH 52,612 4,756
NP 61,650 5,318
DGNP41,362 5,606
Least square means for Time :
Group Mean SEM
2 min84,460 5,138
1 h 47,247 5,138
24 h 23,918 5,435
Least square means for Sample x Time :
Group Mean SEM
TH x 2 min 100,000 8,238
TH x 1 h 43,035 8,238
TH x 24 h 14,801 8,238
NP x 2 min 92,554 9,211
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NP x 1 h 60,170 9,211
NP x 24 h 32,227 9,211
DGNP x 2 min60,825 9,211
DGNP x 1 h 38,537 9,211
DGNP x 24 h 24,726 10,636
All Pairwise Multiple Comparison Procedures (Holm-Sidak method):
Overall significance level = 0,05
Comparisons for factor: Sample
Comparison Diff of Means t P P<0,050
NP vs. DGNP 20,288 2,626 0,032 Yes
TH vs. DGNP 11,250 1,530 0,244 No
NP vs. TH 9,038 1,267 0,210 No
Comparisons for factor: Time
Comparison Diff of Means t P P<0,050
2 min vs. 24 h 60,542 8,095 <0,001 Yes
2 min vs. 1 h 37,212 5,122 <0,001 Yes
1 h vs. 24 h 23,330 3,119 0,003 Yes
Comparisons for factor: Time within TH
Comparison Diff of Means t P P<0,05
2 min vs. 24 h 85,199 7,313 <0,001 Yes
2 min vs. 1 h 56,965 4,889 <0,001 Yes
1 h vs. 24 h 28,234 2,423 0,018 Yes
Comparisons for factor: Time within NP
Comparison Diff of Means t P P<0,05
2 min vs. 24 h 60,327 4,631 <0,001 Yes
2 min vs. 1 h 32,384 2,486 0,031 Yes
1 h vs. 24 h 27,943 2,145 0,036 Yes
Comparisons for factor: Time within DGNP
Comparison Diff of Means t P P<0,05
2 min vs. 24 h 36,099 2,566 0,037 Yes
2 min vs. 1 h 22,288 1,711 0,175 No
1 h vs. 24 h 13,811 0,982 0,330 No
Comparisons for factor: Sample within 2 min
Comparison Diff of Means t P P<0,05
TH vs. DGNP 39,175 3,170 0,007 Yes
NP vs. DGNP 31,729 2,436 0,035 Yes
TH vs. NP 7,446 0,603 0,549 No
Comparisons for factor: Sample within 1 h
Comparison Diff of Means t P P<0,05
NP vs. DGNP 21,634 1,661 0,274 No
NP vs. TH 17,135 1,387 0,311 No
TH vs. DGNP 4,498 0,364 0,717 No
Comparisons for factor: Sample within 24 h
Comparison Diff of Means t P P<0,05
NP vs. TH 17,426 1,410 0,414 No
DGNP vs. TH 9,925 0,738 0,712 No
NP vs. DGNP 7,501 0,533 0,596 No
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